WO2001013927A9 - Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereof - Google Patents
Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereofInfo
- Publication number
- WO2001013927A9 WO2001013927A9 PCT/US2000/023300 US0023300W WO0113927A9 WO 2001013927 A9 WO2001013927 A9 WO 2001013927A9 US 0023300 W US0023300 W US 0023300W WO 0113927 A9 WO0113927 A9 WO 0113927A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bacillus
- composition
- species
- skin
- article
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/36—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/001—Preparations for care of the lips
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- Probiotic microorganisms are those which confer a benefit when grow in a particular environment, often by inhibiting the growth of other biological organisms in the same environment.
- probiotic organisms include bacteria and bacteriophages which possess the ability to grow within the gastrointestinal tract, at least temporarily, to displace or destroy pathogenic organisms, as well as providing other benefits to the host. See e.g., Salminen et al, 1996. Antonie Van Leeuwenhoek 70: 347-358; Elmer et al, 1996. JAMA 275: 870-876; Rafter, 1995. Scand. J. Gastroenterol. 30: 497-502; Perdigon et al, 1995. J Dairy Sci. 78: 1597-1606; Gandi, Townsend Lett. Doctors & Patients, pp. 108-110, Jan. 1994; Lidbeck et ⁇ , 1992. Eur. J. Cancer Prev. 1: 341-353.
- probiotics are members of the normal colonic microflora and are not viewed as being overtly pathogenic. However, these organisms have occasionally caused infections (e.g., bacteremia) in individuals who are, for example, immunocompromised. See e.g., Sussman, J. et al, 1986. Rev Infect. Dis. 8: 111-116; Hata, D. et al, 1988. Pediatr. Infect. Dis. 7: 669-671.
- probiotic bacteria found in sour milk has been utilized since ancient times (i.e., long-before the discovery of bacteria) as a therapeutic treatment for dysentery and related gastrointestinal diseases. More recently, probiotic preparations were systematically evaluated for their effect on health and longevity in the early- 1900's (see e.g., Metchinikoff, E., Prolongation of Life, Willaim Heinermann, London 1910), although their utilization has been markedly limited since the advent of antibiotics in the 1950's to treat pathological microbes. See e.g., Winberg, et al, 1993. Pediatr. Nephrol. 7: 509-514; Malin et al, Ann. Nutr. Metab.
- lactic acid-producing bacteria e.g., Bacillus, Lactobacillus and Streptococcus species
- gastrointestinal microflora has been shown to play a number of vital roles in maintaining gastrointestinal tract function and overall physiological health.
- the growth and metabolism of the many individual bacterial species inhabiting the gastrointestinal tract depend primarily upon the substrates available to them, most of which are derived from the diet. See e.g., Gibson G.R. et al, 1995. Gastroenterology 106: 975-982; Christl, S.U. et al, 1992. Gut 33: 1234-1238.
- Bifidobacteria are known to be involved in resisting the colonization of pathogens in the large intestine. See e.g., Yamazaki, S. et al, 1982. Bifidobacteria and Microflora 1: 55-60.
- lactic acid producing bacteria also produce bacteriocins which are inhibitory metabolites which are responsible for the bacteria's anti-microbial effects. See e.g., Klaenhammer, 1993. FEMS Microbiol. Rev. 12: 39-85; Barefoot et al, 1993. J. Diary Sci. 76: 2366-2379.
- selected Lactobacillus strains which produce antibiotics have been demonstrated as effective for the treatment of infections, sinusitis, hemorrhoids, dental inflammations, and various other inflammatory conditions. See e.g., U.S. Patent No. 5,439,995.
- Lactobacillus reuteri has been shown to produce antibiotics which possess anti-microbial activity against Gram negative and Gram positive bacteria, yeast, and various protozoan. See e.g., U.S. Patent Nos. 5,413,960 and 5,439,678. Probiotics have also been shown to possess anti-mutagenic properties. For example,
- Gram positive and Gram negative bacteria have been demonstrated to bind mutagenic pyrolysates which are produced during cooking at a high temperature. Studies performed with lactic acid-producing bacteria has shown that these bacteria may be either living or dead, due to the fact that the process occurs by adsorption of mutagenic pyrolysates to the carbohydrate polymers present in the bacterial cell wall. See e.g., Zang, X. Bacillus et al, 1990. J. Dairy Sci. 73: 2702-2710. Lactobacilli have also been shown to possess the ability to degrade carcinogens ⁇ e.g., N-nitrosamines), which may serve an important role if the process is subsequently found to occur at the level of the mucosal surface.
- carcinogens ⁇ e.g., N-nitrosamines
- B- and T-lymphocytes, and accessory cells of the immune system have all been implicated in the aforementioned immunity. See e.g., Schiffrin, E.J. et al, 1997. Am. J. Clin. Nutr. 66: 5- 20S.
- Other bacterial metabolic products which possess immunomodulatory properties include: endotoxic lipopolysaccharide, peptidoglycans, and lipoteichoic acids. See e.g., Standiford, T.K., 1994. Infect. Linmun. 62: 119-125.
- probiotic organisms are thought to interact with the immune system at many levels including, but not limited to: cytokine production, mononuclear cell proliferation, macrophage phagocytosis and killing, modulation of autoimmunity, immunity to bacterial and protozoan pathogens, and the like. See e.g., Matsumara, K. et al, 1992. Animal Sci. Technol (Jpn) 63: 1157-1159; Solis-Pereyra, B. and Lemmonier, D., 1993. Nutr. Res. 13: 1127-1140.
- Lactobacillus strains have also been found to markedly effect changes in inflammatory and immunological responses including, but not limited to, a reduction in colonic inflammatory infiltration without eliciting a similar reduction in the numbers of B- and T-lymphocytes. See e.g., De Simone, C. et al, 1992. Immunopharmacol Immunotoxicol 14: 331-340.
- Antibiotics are widely used to control pathogenic microorganisms in both humans and animals.
- the widespread use of anti-microbial agents, especially broad spectrum antibiotics has resulted in a number of serious clinical consequences.
- the indiscriminate use of these chemicals has resulted in the generation of multiple antibiotic- resistant pathogens. See e.g., Mitchell, P. 1998. The Lancet 352: 462-463; Shannon, K., 1998. The Lancet 352: 490-491.
- MRS A Meticillin-resistant Staphylococcus aurous
- Enterococci are currently a major nosocomial pathogen and are likely to remain as such for a long period of time. Enterococci, as well as other microbes, obtain antibiotic resistance genes in several different ways. For example, Enterococci emit pheromones which cause them to become “sticky” and aggregate, thus facilitating the exchange of genetic material, such as plasmids (autonomously replicating, circular D ⁇ A which often carry the antibiotic resistance genes). In addition, some Enterococci also possess "conjugative transposons" which are D ⁇ A sequences that allow them to directly transfer resistance genes without plasmid intermediary. It is believed that penicillin resistance has been conferred from Enterococci to Streptococci to Staphylococci through this later mechanism.
- antibiotics often kill beneficial, non-pathogenic microorganisms ⁇ i.e., flora) within the gastrointestinal tract which contribute to digestive function and health. Accordingly, relapse (the return of infections and their associated symptoms) and secondary opportunistic infections often result from the depletion of lactic acid-producing and other beneficial flora within the gastrointestinal tract. Most, if not all, lactic acid-producing or probiotic bacteria are extremely sensitive to common antibiotic compounds. During a normal course of antibiotic therapy, many individuals develop a number of deleterious physiological side-effects including: diarrhea, intestinal cramping, and sometimes constipation.
- beneficial and/or pathological microorganisms can also inhabit the oral cavity, the genital area and the vagina (see e.g., Thomason, et al, 1991. Am. J. Obstet Gynecol. 165: 1210-1217; Marsh, 1993. Caries Res. 27: 72-76; Lehner, 1985. Vaccine 3: 65-68; Hill & Embil, 1986. Can. Med. Assoc. J. 134: 321- 331).
- anti-microbial drugs can similarly cause an imbalance in those microorganisms and the therapeutic use of probiotic bacteria, especially the Lactobacillus strains, which colonize those areas has been disclosed (see e.g., Winberg, et al, 1993. Pediatr. Nephrol. 1: 509-514; Malm, et al, 1996. Ann. Mar. Metab. 40: 137-145, U.S. Patent No. 5,176,911).
- Increasing numbers of pathogenic microorganisms have developed antibiotic resistance, requiring the development and use of second and third generation antibiotics.
- Microorganisms that are resistant to multiple drugs have also developed, often with multiple drug resistance spreading between species, leading to serious infections that cannot be controlled by use of antibiotics.
- opportunistic microbial infections often occur in immunodeficient individuals.
- Immunodeficient individuals have impaired natural immunity allowing pathogenic microorganisms to survive and grow, either internally or externally, due to the individual's diminished immune response to the pathogen.
- Immunodeficiency can result from genetic conditions, diseases such as AIDS, or therapeutic treatments such as cancer therapy (chemotherapy or radiation treatment) and drug-mediated immunosuppression following organ transplant.
- Inhibition of pathogenic microorganisms by probiotics is useful for preventing or treating opportunistic infections, particularly in immunodeficient individuals.
- lactic acid-producing bacteria e.g., those used to make yogurt
- some lactic acid-producing bacteria have been suggested to have anti-mutagenic and anti-carcinogenic properties useful in the prevention of human tumors (see e.g., Pool-Zobel, et al, 1993. Nutr. Cancer 20: 261-270; U.S. Patent No. 4,347,240).
- Some lactic acid-producing bacteria have also been demonstrated to produce bacteriocins, which are inhibitory metabolites responsible for the bacteria's anti- microbial effects (Klaenhammer, 1993. FEMS Microbiol. Rev. V2: 39-85; Barefoot & Nettles, 1993. J. Dairy Sci. 16: 2366-2319).
- Lactobacillus strains that produce antibiotics have been disclosed as effective for treatment of infections, sinusitis, hemorrhoids, dental inflammations, and other inflammatory conditions (see U.S. Patent No. 4,314,995).
- Lactobacillus reuteri has been shown to produce antibiotics with activity against Gram negative and Gram positive bacteria, yeast and a protozoan (see U.S. Patent No. 5,413,960 and U.S. Patent No. 5,439,678).
- Lactobacillus casei asp. rhamnosus strain LC-705, DSM 7061, alone or in combination with a Propionibacterium species, in a fermentation broth, has been shown to inhibit yeast and molds in food and silage (U.S. Patent No.
- anti-fungal Serratia species have been added to animal forage and/or silage to preserve the animal feed, particularly Serratia rubidaea FB299, alone or combined with an anti-fungal Bacillus subtilis (strain P3260). See U.S. Patent No. 5,371,011), whose disclosure is incorporated herein by reference, in its entirety. 4. Bacillus coagulans
- Bacillus coagulans is a non-pathogenic gram positive spore-forming bacteria that produces L(+) lactic acid (dextrorotatory) in homofermentation. This microorganism has been isolated from natural sources, such as heat-treated soil samples inoculated into nutrient medium (see e.g., Bergey 's Manual of Systemic Bacteriology, Vol. 2, Sneath, P.H.A., et al, eds., (Williams & Wilkins, Baltimore, MD, 1986)). Purified Bacillus coagulans strains have served as a source of various enzymes including, but not limited to: restriction endonucleases (see U.S. Patent No.
- Bacillus coagulans designated Lactobacillus sporogenes, Sakaguti & Nakayama (ATCC 31284)
- Bacillus natto to produce a fermented food product from steamed soybeans
- Bacillus coagulans strains have also been used as animal feed additives for poultry and livestock to reduce disease and improve feed utilization and to, therefore, increase growth rate in the animals (see International Patent Application Nos. WO 9314187 and WO 9411492).
- biorational therapy which functions to mitigate digestive pathogens, in both humans and animals, by the colonization (or re-colonization) of the gastrointestinal tract with probiotic microorganisms, following the administration of antibiotics, anti-fungal, anti-viral, and similar agents.
- Dermal infections especially those caused by mycotic pathogens, make-up a considerable percentage of the sale of prescription and over-the-counter medications that are sold armuallv worldwide.
- Center for Disease Control and Prevention include, but are not limited to: Fluconazole (Diflucan ® ; Pfizer Pharmaceutical), Intraconazole (Sporonox ® ; Janssen Pharmaceutical), Miconazole Nitrate, Ketoconazole, Tolnaftate, Lamasil, Griseofulvin, Amphotercin B, and other compounds and the formulations thereof.
- Candidaiasis e.g., caused by Candida albicans, Candida tropicalis, Candida golbratta, Candida parapsilosis
- Tineal diseases also known as Athletes Foot (Tinea Pedis), Jock Itch (Tinea Cruis), Scalp Infection (Tinea Capitis), Ring Worm, and Beard infections (Tinea Barbae)
- Trichophyton species including, but not limited to:
- Trichophyton mentagrophytes Trichophyton mentagrophytes
- ⁇ Hi diseases which are caused by bacterial pathogens, including, but not limited to: Pseudomonas aeruginosa, Staphylococcus aerues, Staphylococcus epidermidus, and Propionibacterium acnes
- diseases which are caused by viral pathogens including, but not limited to: Herpes simplex I & II, and Herpes zoster.
- Perhaps one of the most difficult-to-treat diseases of fungal etiology are fungal infections of the toenail or fingernail ⁇ i.e., Onychomycosis) due to the inability of the currently-available therapeutic compositions to penetrate the dermis or cuticle.
- the pathogen most commonly associated with this very difficult to treat disease is Trichophyton rubrum.
- the present invention discloses the finding that Bacillus species possess the ability to exhibit probiotic activity in aerobic conditions such as on skin or mucous membrane tissues and thereby treat, control and/or inhibit numerous conditions caused by bacterial, fungal, yeast, and viral infections, or combinations thereof.
- the present invention discloses therapeutic compositions, articles of manufacture and methods of use for inhibiting various microbial infections caused by bacteria, yeast, fungus or virus, which utilize isolated Bacillus species or Pseudomonas lindbergii strain.
- Bacillus species useful in the practice of the present invention including: Bacillus coagulans, Bacillus subtilis, Bacillus laterosporus and Bacillus laevolacticus.
- Bacillus coagulans is only a model for the other Bacillus species, and therefore the use of this species in the majority of the specific examples provided herein are not to be considered as limiting.
- the present invention discloses a composition comprising an isolated Bacillus species or Pseudomonas lindbergii strain in a pharmaceutically-acceptable carrier suitable for topical application to skin or mucous membranes of a mammal.
- the Bacillus species is included in the composition in the form of spores.
- the Bacillus species is included in the composition in the form of a dried cell mass.
- the carrier may be an emulsion, cream, lotion, paste, gel, oil, ointment, suspension, aerosol spray, powder, aerosol powder or semi- solid formulation.
- a therapeutic composition comprising an extracellular product of a Bacillus coagulans species in a pharmaceutically-acceptable carrier suitable for topical application to skin or a mucosal membrane of a mammal is disclosed.
- the extracellular product comprises the supernatant, filtrate, or partially-purified secreted agents of a culture of an isolated Bacillus coagulans species.
- the carrier may be an emulsion, paste, cream, lotion, gel, oil, ointment, suspension, aerosol spray, powder, aerosol powder, or semi-solid formulation.
- an extracellular product of Pseudomonas lindbergii strain comprising a supernatant, filtrate, or partially-purified secreted agents of a culture of said Pseudomonas lindbergii strain is utilized as a therapeutic composition for the prevention and/or control of infections caused by bacterium, fungi, yeast, and virus, and combinations thereof.
- the therapeutic composition is comprised of the extracellular product of the Pseudomonas lindbergii strain in a pharmaceutically-acceptable carrier suitable for topical application to skin or a mucosal membrane of a mammal is disclosed.
- the carrier may be an emulsion, cream, lotion, gel, oil, ointment, suspension, aerosol spray, powder, aerosol powder, or semi-solid formulation.
- a method of preventing bacterial, yeast, fungal or viral infection including the steps of applying topically to skin or a mucous membrane of a mammal a probiotic composition comprising an isolated Bacillus species; and allowing the probiotic bacteria Bacillus species to grow topically for sufficient time to inhibit growth of bacteria, yeast, fungus or virus.
- An additional embodiment further includes the steps of providing spores of the Bacillus species in the probiotic composition, and allowing the spores to germinate after the applying step.
- the step of allowing the Bacillus species to grow inhibits growth of one or more microbe species selected from the group consisting of Staphylococcus species, Streptococcus species, Pseudomonas species, Escherichia coli, Gardnerella vaginalis, Propionibacterium acnes, Blastomyces species, Pneumocystis carinii, Aeromonas hydrophilia, Trichosporon species, Aspergillus species, Proteus species, Acremonium species, Cryptococcus neoformans, Microsporum species, Aerobacter species, Clostridium species, Klebsiella species, Candida species and Trichophyton species.
- one or more microbe species selected from the group consisting of Staphylococcus species, Streptococcus species, Pseudomonas species, Escherichia coli, Gardnerella vaginalis, Propionibacterium acnes, Blastomyces species, Pneumocystis car
- the applying step is applying a probiotic composition in the form of a cream, lotion, gel, oil, ointment, suspension, aerosol spray, powder, aerosol powder or semi-solid formulation.
- methods for inhibiting growth of bacteria, yeast, fungus, virus or a combination thereof include the steps of applying topically to skin or a mucous membrane a composition comprising an extracellular product of an isolated Bacillus coagulans or Pseudomonas lindbergii strain, and allowing the composition to be present for sufficient time to inhibit growth of bacteria, yeast, fungus, virus or any combination thereof.
- the applying step includes applying the composition in the form of a cream, lotion, gel, oil, ointment, suspension, aerosol spray, powder, aerosol powder or semi-solid formulation.
- composition comprising an isolated Bacillus species is applied to a flexible article that is intended to be worn by or attached to skin or a mucous membrane of a mammal to allow probiotic activity of the bacteria to occur adjacent to or on the skin or mucous membrane.
- a method of inhibiting growth of bacteria, yeast, fungus, virus or any combination thereof including the steps of applying a composition comprising an isolated Bacillus species to a solid surface, contacting the solid surface with the applied Bacillus species thereon to skin or a mucous membrane of a mammal, and allowing the solid surface to contact the skin or mucous membrane for sufficient time to allow initiation of probiotic activity of the isolated bacteria to inhibit growth of bacteria, yeast, fungus, virus or a combination thereof adjacent to or on the skin or mucous membrane.
- the applying step includes applying the composition to a diaper, pliable material for wiping skin or a mucous membrane, dermal patch, adhesive tape, absorbent pad, tampon or article of clothing. In another embodiment, the applying step includes impregnating the composition into a fibrous or non-fibrous solid matrix.
- the present invention also discloses a therapeutic system for treating, reducing or controlling microbial infections comprising a container comprising a label and a therapeutic composition as described herein, wherein said label comprises instructions for use of the composition for treating infection.
- the present invention provides several advantages. In particular, insofar as there is a detrimental effect to the use of antibiotics because of the potential to produce antibiotic- resistant microbial species, it is desirable to have an anti-microbial therapy which does not utilize conventional anti-microbial reagents. The present invention does not contribute to the production of future generation of antibiotic resistant pathogens.
- FIG. 1 illustrates various metabolic activities and the associated, characteristic physiological or biochemical response in Bacillus coagulans.
- FIG. 2 illustrates the various pathogens, which may be treated by use of the therapeutic compositions of the present invention, and their associated disorders.
- FIG. 3 enumerates the tested fungal strains of Trichophyton species (available from the American Type Culture Collection (ATCC; Rockville, Maryland)), their respective ATCC accession numbers, and the results of in vitro inhibition by Bacillus coagulans.
- ATCC American Type Culture Collection
- FIG. 4 enumerates the tested yeast strains of ability of Candida species (available from the American Type Culture Collection (ATCC; Rockville, Maryland)), their respective ATCC accession numbers, and the results of in vitro inhibition by Bacillus coagulans.
- FIG. 5 illustrates a wavelength scan of Bacillus coagulans (Panel A)
- FIG. 6 illustrates a wavelength scan of Bacillus coagulans (Panel A)
- FIG. 7 illustrates a 12% acrylamide SDS PAGE of Pseudomonas lindbergii proteins.
- the left lane are molecular weight markers.
- FIG. 8 illustrates a 12% acrylamide SDS PAGE of Bacillus coagulans proteins.
- the left lane are molecular weight markers.
- FIG. 9 illustrates a reverse-phase HPLC of acetonitrile-extracted Pseudomonas lindbergii supernatant.
- FIG. 10 illustrates a reverse-phase HPLC of acetonitrile-extracted Bacillus coagulans supernatant.
- FIG. 11 illustrates, in tabular form, a comparison of the anti-mycotic,
- Fluconazole with Bacillus coagulans and Pseudomonas lindbergii supernatants (generically designated Ganeden Supernatant) in the inhibition of various bacterial, fungal, and yeast species.
- probiotic refers to microorganisms (e.g., bacteria, yeast, viruses, and/or fungi) which form, at a minimum, a part of the transient or endogenous flora and, thus, possess a beneficial prophylactic and/or therapeutic effect upon the host organism.
- Probiotics are generally known to be clinically-safe (i.e., non-pathogenic) by those skilled within the art.
- the probiotic activity of Bacillus species is thought to result from competitive inhibition of growth of pathogens due to superior colonization, parasitism of undesirable microorganisms, lactic acid production and/or other extracellular products having anti-microbial activity, or combinations thereof.
- microbial refers to bacteria, yeast, fungi, and/or virus.
- the present invention discloses the ability to utilize Bacillus species in therapeutic compositions as a probiotic, for the prevention and/or control infections caused by pathogens including, but not limited to, microbial, yeast, fungal, or viral infections.
- pathogens including, but not limited to, microbial, yeast, fungal, or viral infections.
- these compositions can be formulated in a variety of configurations, due to the fact that the bacterium is presented as a viable organism, either as a vegetative cell or as a spore, and colonizes the tissue of interest.
- the cells/spores may be presented in therapeutic compositions suited for topical application to a tissue, or in suspensions such as a bath, or on flexible materials such as diapers, bandaids, tampons, and like personal articles, all directed to the objective of introducing the bacteria topically to skin or a mucous membrane tissue.
- the prophylactic and/or therapeutic effect of a lactic acid-producing bacteria of the present invention results, in part, from a competitive inhibition of the growth of pathogens due to: (i) their superior colonization abilities; ( ⁇ ) parasitism of undesirable microorganisms; ( ) the production of lactic acid and/or other extracellular products possessing anti-microbial activity; or (iv) various combinations thereof.
- the aforementioned products and activities of the lactic acid-producing Bacillus of the present invention act synergistically to produce the beneficial probiotic effect disclosed herein.
- a probiotic bacteria which is suitable for use in the methods and compositions of the present invention (i) possesses the ability to produce lactic acid; (ii) demonstrates beneficial function; and (z ⁇ ) is non-pathogenic.
- many suitable bacteria have been identified and are described herein, although it should be noted that the present invention is not to be limited to currently-classified bacterial species insofar as the purposes and objectives as disclosed.
- the physiochemical results from the in vivo production of lactic acid is key to the effectiveness of the probiotic lactic acid-producing bacteria of the present invention.
- Lactic acid production markedly decreases the pH ⁇ i.e., increases acidity) within the local micro-floral environment and does not contribute to the growth of many undesirable, physiologically-deleterious bacteria, fungi, and viruses.
- the probiotic inhibits growth of competing pathogenic bacteria.
- Typical lactic acid-producing bacteria useful as a probiotic of this invention are efficient lactic acid producers which include non-pathogenic members of the Bacillus genus which produce bacteriocins or other compounds which inhibit the growth of pathogenic organisms.
- Exemplary lactic acid-producing, non-pathogenic Bacillus species include, but are not limited to: Bacillus coagulans; Bacillus coagulans Hammer; and Bacillus brevis subspecies coagulans.
- Bacillus species which are preferred in the practice of the present invention, include, but are not limited to the lactic acid-producing Bacillus coagulans and Bacillus laevolacticus. Various other non-lactic acid-producing Bacillus species may be utilized in the present invention so long as they produce compounds which possess the ability to inhibit pathogenic bacterial or mycotic growth.
- non-lactic acid-producing Bacillus examples include, but are not limited to: Bacillus subtilis, Bacillus uniflagellatus, Bacillus lateropsorus, Bacillus laterosporus BOD, Bacillus megaterium, Bacillus polymyxa, Bacillus licheniformis, Bacillus pumilus, Bacillus mycoides, and Bacillus sterothermophilu .
- the Bacillus species are a preferred embodiment of the present invention.
- the Bacillus species utilized in the practice of the present invention may selected from the group comprising: Bacillus coagulans, Bacillus subtilis, Bacillus laterosporus and Bacillus laevolacticus, all of which have the ability to form spores, and can colonize tissue aerobically.
- Bacillus coagulans e.g., Bacillus subtilis
- Bacillus laterosporus e.g., Bacillus laevolacticus
- There are a variety of different Bacillus species including, but not limited to many different strains available through commercial and public sources, such as the American Tissue Culture Collection (ATCC).
- ATCC American Tissue Culture Collection
- Bacillus coagulans strains are available as ATCC Accession Numbers 15949, 8038, 35670, 11369, 23498, 51232, 11014, 31284, 12245, 10545 and 7050.
- Bacillus subtilis strains are available as ATCC Accession Numbers 10783, 15818, 15819, 27505, 13542, 15575, 33234, 9943, 6051a, 25369, 11838, 15811, 27370, 7003, 15563, 4944, 27689, 43223, 55033, 49822, 15561, 15562, 49760, 13933, 29056, 6537, 21359, 21360, 7067, 21394, 15244, 7060, 14593, 9799, 31002, 31003, 31004, 7480, 9858, 13407, 21554, 21555, 27328 and 31524.
- Bacillus laterosporus strains are available as ATCC Accession Numbers 6456, 6457, 30 29653, 9141, 533694, 31932 and 64, including Bacillus laterosporus BOD.
- Bacillus laevolacticus strains are available as ATCC Accession Numbers 23495, 23493, 23494, 23549 and 23492. It should be noted, however, that although many of the examples herein refer to the Bacillus coagulans species in particular, it is intended that any of the Bacillus species can be used in the compositions, articles of manufacture, systems and method of the present invention.
- a Bacillus species is particularly suited for the present invention due to the properties in common between species of the Bacillus genus, including, but not limited to, the ability to form spores which are relatively resistant to heat and other conditions, making them ideal for storage (shelf-life) in product formulations, and ideal for survival and colonization of tissues under conditions of pH, salinity, and the like on tissues subjected to microbial infection.
- probiotic Bacillus coagulans is non-pathogenic and is generally regarded as safe ⁇ i.e., GRAS classification) by the U.S. Federal Drug Administration (FDA) and the U.S. Department of Agriculture (USD A), and by those individuals skilled within the art.
- Bacillus species include, but are not limited to: non- pathogenicity, being aerobic, facultative and heterotropl ic, thus rendering these species safe, and able to colonize skin, mucous membrane tissues, and various other tissues of interest. Because Bacillus species possesses the ability to produce heat-resistant spores, it is particularly useful for making pharmaceutical compositions which require heat and pressure in their manufacture. Accordingly, formulations that include the utilization viable Bacillus spores in a pharmaceutically-acceptable carrier are particularly preferred for making and using compositions disclosed in the present invention. The growth of these various Bacillus species to form cell cultures, cell pastes, and spore preparations is generally well-known within the art.
- Bacillus coagulans may be readily utilized and/or modified for growth and preparation of the other Bacillus strains, as well as the lactic acid-producing bacteria disclosed in the present invention.
- exemplary methods and compositions which are described herein using Bacillus coagulans as a probiotic for controlling, treating, or reducing microbial infections may also be readily utilized with other Bacillus species.
- Bacillus coagulans Compositions Although, as disclosed herein, any of the aforementioned Bacillus strains may be utilized in the practice of the present invention, purified Bacillus coagulans is exemplary and preferred as a probiotic for biological control of various microbial pathogens. Because Bacillus coagulans forms heat-resistant spores, it is particularly useful for making pharmaceutical compositions for treating microbial infections. Topical formulations which include viable Bacillus coagulans spores in a pharmaceutically-acceptable carrier, are particularly preferred for making and using preventive and therapeutic compositions of the present invention. The term "topical" is broadly utilized herein to include both epidermal and/or skin surfaces, as well as mucosal surfaces of the body.
- the Gram positive rods of Bacillus coagulans have a cell diameter of greater than
- Bacillus coagulans is a non-pathogenic, Gram positive, spore-forming bacteria that produces L(+) lactic acid (dextrorotatory) under homo-fermentation conditions. It has been isolated from natural sources, such as heat-treated soil samples inoculated into nutrient medium (see e.g., Bergey's Manual of Systemic Bacteriology, Vol. 2, Sneath, P.H.A. et al, eds., Williams & Wilkins, Baltimore, MD, 1986). Purified Bacillus coagulans strains have served as a source of enzymes including endonucleases (e.g., U.S. Patent No.
- Bacillus coagulans has also been utilized to produce lactic acid (U.S. Patent No. 5,079,164).
- a strain of Bacillus coagulans also referred to as
- Lactobacillus sporogenes has been combined with other lactic acid producing bacteria and Bacillus natto to produce a fermented food product from steamed soybeans (U.S. Patent No. 4,110,477).
- Bacillus coagulans strains have also been used as animal feeds additives for poultry and livestock to reduce disease and improve feed utilization and, therefore, to increase growth rate in the animals (International PCT Patent Applications No. WO 9314187 and No. WO 9411492).
- Bacillus coagulans strains have been used as general nutritional supplements and agents to control constipation and diarrhea in humans and animals.
- Bacillus coagulans bacteria utilized in the present invention are available from the American Type Culture Collection (ATCC, Rockville, MD) using the following accession numbers: Bacillus coagulans Hammer NRS 727 (ATCC No. 11014); Bacillus coagulans Hammer strain C (ATCC No. 11369); Bacillus coagulans Hammer (ATCC No. 31284); and Bacillus coagulans Hammer NCA 4259 (ATCC No. 15949).
- - Purified Bacillus coagulans bacteria are also available from the Deutsche Sarumlung von Mikroorganismen und Zellkuturen GmbH (Braunschweig, Germany) using the following accession numbers: Bacillus coagulans Hammer 1915 (DSM No. 2356); Bacillus coagulans Hammer 1915 (DSM No.
- Bacillus coagulans bacteria can also be obtained from commercial suppliers such as Sabinsa Corporation (Piscataway, NJ) or K.K. Fermentation (Kyoto, Japan).
- Bacillus coagulans strains and their growth requirements have been described previously (see e.g., Baker, D. et al, 1960. Can. J. Microbiol. 6: 557-563; Nakamura, H. et al, 1988. Int. J. Svst. Bacterial 38: 63-73.
- various strains of Bacillus coagulans can also be isolated from natural sources (e.g., heat-treated soil samples) using well-known procedures (see e.g., Bergey's Manual of Systemic Bacteriology, Vol. 2, p. 1117, Sneath, P.H.A. et al, eds., Williams & Wilkins, Baltimore, MD, 1986).
- Bacillus coagulans had previously been mis-characterized as a Lactobacillus in view of the fact that, as originally described, this bacterium was labeled as Lactobacillus sporogenes (See Nakamura et al. 1988. Int. J. Syst. Bacteriol 38: 63-73).
- initial classification was incorrect due to the fact that Bacillus coagulans produces spores and through metabolism excretes L(+)-lactic acid, both aspects which provide key features to its utility. Instead, these developmental and metabolic aspects required that the bacterium be classified as a lactic acid bacillus, and therefore it was re-designated.
- Bacillus coagulans is aerobic and facultative, grown typically in nutrient broth, pH 5.7 to 6.8, containing up to 2% (by wt) NaCl, although neither NaCl nor KCI are an absolute requirement for growth.
- a pH value ranging from approximately pH 4 to pH 6 is optimum for initiation of sporulation. It is optimally grown at about 30°C to about 55°C, and the spores can withstand pasteurization. It exhibits facultative and heterotrophic growth by utilizing a nitrate or sulfate source. Additional metabolic characteristics of Bacillus coagulans are summarized in FIG. 1.
- Bacillus coagulans can be grown in a variety of media, although it has been found that certain growth conditions produce a culture which yields a high level of sporulation. For example, sporulation is enhanced if the culture medium includes 10 mg/liter of manganese sulfate, yielding a ratio of spores to vegetative cells of about 80:20.
- certain growth conditions produce a bacterial spore which contains a spectrum of metabolic enzymes particularly suited for the present invention ⁇ i.e., the control of microbial infections). Although spores produced by these particular growth conditions are preferred, spores produced by any compatible growth conditions are suitable for producing a Bacillus coagulans useful in the present invention. It should also be noted that the most preferred embodiment of the present invention utilizes Bacillus coagulans in spore, rather than vegetative bacterial form.
- Bacillus coagulans cultures contain secreted products which possess anti-microbial activity. These secreted products are useful in therapeutic compositions according to the present invention. Cell cultures are harvested as described above, and the culture supernatants are collected, by filtration or centrifugation, or both, and the resulting supernatant contains anti-microbial activity useful in the therapeutic compositions of the present invention. The preparation of a Bacillus coagulans extracellular products will be more fully described in the Specific Examples section, infra. 4. Probiotic Activity of Bacillus coagulans
- Pathogenic bacteria inhibited by Bacillus coagulans activity include, for example, Staphylococcus aureus, Staphylococcus epidermidus, Streptococcus pyogenes, Pseudomonas aeruginosa, Escherichia coli (i.e., entero-hemorragic species), numerous Clostridium species (e.g., Clostridiumperfingens, Clostridium botulinum, Clostridium tributrycum, Clostridium sporogenes, and the like); Gardnereia vaginails; Proponbacterium acnes; Aeromonas hydrophia; Aspergillus species; Proteus species; and Klebsiella species.
- Staphylococcus aureus Staphylococcus epidermidus
- Streptococcus pyogenes Pseudomonas aeruginosa
- Escherichia coli i.e., entero
- Pathogenic yeast and other fungi inhibited by Bacillus coagulans activity include Candida albicans, Candida tropicalis and Trichophyton mentagrophytes, Trichophyton interdigitale, Trichophyton rubrum, and Trichophyton yaoundei.
- HSV-I Herpes simplex viruses I
- HSV-II Herpes simplex II
- shingles Herpes zoster
- pathogens have been associated with a variety of disorders including, but not limited to: diaper rash; oral, genital, cervical and vaginal yeast infections; toxic shock syndrome; chronic mucocutaneous candidaiasis; dermatophytosis; bacterial vaginosis; tineal fungal infections (e.g., ringworm, athlete's foot, and jock itch); scalp and nail fungal infections; superficial skin disorders (e.g., erysipelas, open-wound infections, acne, abscess, boil, eczema, dermatitis, contact dermatitis, hypersensitinitis, contact lesions, bed sores, and diabetic lesions); miscellaneous opportunistic infections; oral and genital viral lesions, and the like conditions as are well known in the art. Therefore, topical use of compositions containing the Bacillus coagulans active agents that inhibit these pathogens are useful in preventing or treating these conditions.
- FIG. 2 The various pathogens, which may be treated by use of the therapeutic compositions of the present invention, and their associated disorders are illustrated in FIG. 2. It should be noted, however, that the pathogens listed in FIG. 2 are set forth as examples only, and are not meant to be limiting to the types of organisms which can be treated by use of the methodologies or compositions of the present invention. Accordingly, various other skin- and mucous membrane-infecting microbes and dermatophytes can also be treated by use of the present compositions and methods disclosed herein.
- Bifidogenic oligosaccharides are long chain polymers that are utilized almost exclusively by the indigenous Bifidobacteria and Lactobacillus in the intestinal tract and can be similarly utilized by Bacillus.
- physiologically deleterious bacteria such as Clostridium, Staphylococcus, Salmonella and Escherichia coli cannot metabolize FOS, or other bifidogenic oligosaccharides, and therefor use of these bifidogenic oligosaccharides in combination with a lactic acid-producing bacteria of the present , preferably Bacillus coagulans, allows these beneficial, probiotic bacteria to grow and effectively compete with, and eventually replace any undesirable, pathogenic microorganisms within the gastrointestinal tract.
- compositions of the present invention provides a synergistic effect thereby increasing the effectiveness of the probiotic-containing compositions disclosed herein.
- This synergy is manifested by selectively increasing the ability of the probiotic bacterium to grow by, for example, increasing the level of nutrient supplementation which preferentially selects for growth of the probiotic bacteria over many other bacterial species within the infected tissue.
- Bifidobacteria and Lactobacillus are also producers of lactic acid.
- Bifidogenic oligosaccharides enable these aforementioned probiotic organisms to proliferate preferentially over the undesirable bacteria within the gastrointestinal tract, thereby augmenting the probiotic state of the body by further enhancing the solubility of these nutrients (whether of food origin or as a result of nutritional supplement augmentation).
- the presence of the bifidogenic oligosaccharides in the compositions of the present invention allows for more effective microbial inhibition by increasing the ability of all varieties of probiotic bacteria to grow, and therefore provide said benefit.
- the bifidogenic oligosaccharide of the present invention may be used either alone, or in combination with a lactic acid-producing microorganisms in a therapeutic composition. More specifically, due to the growth promoting activity of bifidogenic oligosaccharides, the present invention contemplates a composition comprising a bifidogenic oligosaccharide present in a concentration sufficient to promote the growth of lactic acid-producing microorganisms. As shown herein, these concentrations amounts can vary widely, as the probiotic microorganisms will respond to any metabolic amount of nutrient oligosaccharide, and therefore the present invention need not be so limited.
- a preferred and exemplary bifidogenic oligosaccharide is fructo-oligosaccharide (FOS), although other carbohydrates may also be utilized, either alone or in combination.
- FOS can be obtained from a variety of natural sources, including commercial suppliers. As a product isolated from natural sources, the components can vary widely and still provide the beneficial agent, namely FOS.
- FOS typically has a polymer chain length of from about 4 to 200 sugar units, with the longer lengths being preferred. For example, the degree of purity can vary widely so long as biologically-functional FOS is present in the final formulation.
- Preferced FOS formulations contain at least 50% by weight of fructo-oligosaccharides compared to simple(mono or disacchari.de) sugars such as glucose, fructose or sucrose, preferably at least 80% fructo-oligosaccharides (FOS), more preferably at least 90% and most preferably at least 95% FOS.
- FOS fructo-oligosaccharides
- Sugar content and composition can be determined by any of a variety of complex carbohydrate analytical detection methods as is well known.
- FOS Frutafit IQTM (Imperial Suiker Unie; Sugar Land, Texas); NutraFloraTM (Americal Ingredients, Inc.; Anaheim, CA); and Fruittrimfat Replacers and Sweeteners (Emeryville, CA).
- Bifidogenic oligosaccharides such as GOS, and other long chain oligosaccharides are also available from commercial vendors. 6.
- compositions of the present invention which are suitable for use in preventing, treating, and/or controlling microbial infections comprise an active ingredient, specifically: (z) a Bacillus species bacterium (e.g., vegetative cell) or spore; (ii) vegetative cells or spores of Bacillus coagulans; (Hi) extracellular anti-microbial or antibiotic metabolites of Bacillus coagulans; or (iv) combinations thereof in various formulations.
- the active Bacillus ingredients comprise about 0.1 % to about 50% by weight of the final composition, preferably 1% to 10% by weight, in a formulation suitable for topical administration.
- the formulation for a therapeutic composition of this invention may include other probiotic agents or nutrients for promoting spore germination and/or Bacillus growth.
- the compositions may also include known anti-microbial, anti-viral, anti-fungal, or anti-yeast agents, all of which must be compatible with maintaining viability of the specific Bacillus active agent, when Bacillus organisms or spores are utilized as the active agent.
- the various other agents within the therapeutic compositions of the present invention may either be synergists or active agents.
- the known anti-microbial, anti-viral, anti-yeast, and/or anti-fungal agents are probiotic agents compatible with Bacillus.
- the therapeutic compositions may also include, but are not limited to the inclusion of: known antioxidants (e.g., vitamin E); buffering agents; lubricants (e.g., synthetic or natural beeswax); sunscreens ⁇ e.g., para-aminobenzoic acid); and other cosmetic agents (e.g., coloring agents, fragrances, oils, essential oils, moisturizers or drying agents).
- Thickening agents e.g., polyvinylpyrrolidone, polyethylene glycol or carboxymethyicellulose may also be added to the compositions.
- Fragrances and essential oils are particularly suited for the compositions used in personal hygiene products and methods, and can include sea salts, herbs or herb extracts, fragrance oils from a large variety of plants or animals, and fragrances from a large variety of plants or animals, as are all well known.
- Preferred fragrances useful in a composition of this invention include African violet, frankincense & myrrh, lavender, vanilla, gardenia, honeysuckle, sandalwood, musk, jasmine, lotus, orange blossom, patchouli, heather, magnolia, amber, rose, and the like fragrances.
- oils including essential or fragrant oils, include almond, aloe, amber, apple, apricot, bayberry, benzion, cactus blossom, carnation, carrageenan, cedarwood, cinnamon, cloves, coconut, cedar, copal, Emu, eucalyptus, franfipani, frankincense and myrrh, gardenia, grapefruit, heather, herbs, honeysuckle, jasmine, jojoba, kelp, lavender, lemon, lilac, lotus, magnolia, mulberry, musk, myrrh, narcissus, orange blossom, patchouli, peach, pinon pine, plumeria, rose, rosemary, safflower, sage, sandalwood, spirulina, strawberry, vanilla, violet, wisteria, and the like oils.
- a particularly prefened oil for use in the topically-administered therapeutic compositions of the present invention is Emu oil, which is generally utilized in a concentration of approximately 1% to 75%o by weight.
- Emu oil is generally utilized in a concentration of approximately 1% to 75%o by weight.
- the use of Emu oil in the therapeutic compositions of the present invention will be more fully discussed, infra.
- fragrances and essential oils can be provided in various bath salt and bath soap compositions.
- Salts and soaps are also well-known within the art and can include sea salts, desert salts, mineral salts, sodium sesquicarbonate, magnesium sulfate, and the like commonly used bath salts.
- Fragrances, oils, and salts are well known in the art, can be obtained from a variety of natural and commercial sources, and are not considered to limiting to the present invention.
- Exemplary commercial sources include: Alternative Body Science (Carlsbad, CA); Scents of Paradise - SunBurst Technology, Inc., (Salem, OR); Intercontinental Fragrances, Inc., (Houston, TX'); Scentastics, Inc., (Ft. Lauderdale, FL); and Michael Giordano International, Inc., (North Miami, FL).
- Chemicals used in the present compositions can be obtained from a variety of commercial sources, including Spectrum Quality Products, Inc (Gardena, CA); Seltzer Chemicals, Inc., (Carlsbad, CA); and Jarchem Industries, Inc., (Newark, NJ).
- the active agents are combined with a "carrier" which is physiologically compatible with the skin, membrane, or mucosal tissue of a human or animal to which it is topically administered.
- the carrier is substantially inactive, with the exception of its intrinsic surfactant properties which are used in the production of a suspension of the active ingredients.
- the compositions may include other physiologically active constituents that do not interfere with the efficacy of the active agents in the composition.
- a typical therapeutic composition of the present invention will contain in a one gram dosage formulation, from approximately lxlO 3 to lxlO 12 , and preferably approximately 2xl0 5 to lxlO 10 , colony forming units (CFU) of viable Bacillus bacteria (i.e., vegetative bacteria) or bacterial spores.
- the therapeutic composition of the present invention may also include from approximately 10 mg to one gram of a bifidogenic oligosaccharide (e.g., a fructo-oligosaccharide).
- the formulation may be completed in total weight by use of any of a variety of carriers and/or binders.
- a prefened carrier is micro-crystalline cellulose (MCC), which is added in a concentration sufficient to complete the typical one gram dosage total weight.
- MMC micro-crystalline cellulose
- Particularly prefened fonnulations of the therapeutic composition of the present invention will be fully-described in the Specific Examples section, infra.
- the carriers utilized in the therapeutic compositions of the present invention may be solid-based, dry materials for use in powdered formulations or, alternately, may be liquid or gel-based materials for use in liquid or gel formulations.
- the specific formulations depend, in part, upon the routes or modes of administration.
- Typical carriers for dry formulations include, but are not limited to, trehalose, malto- dextrin, rice flour, micro-crystalline cellulose (MCC), magnesium sterate, inositol, fructo- oligosaccharides FOS, gluco-oligosaccharides (GOS), dextrose, sucrose, talc, and the like carriers.
- MCC micro-crystalline cellulose
- GOS gluco-oligosaccharides
- dextrose sucrose
- talc and the like carriers.
- dry fillers which both distribute the components and prevent caking.
- Exemplary anti-caking agents include MCC, talc, diatomaceous earth, amorphous silica and the like, typically added in an concentration of from approximately 1% to 95 > by- weight.
- Suitable liquid or gel-based carriers are well-known in the art (e.g., water, physiological salt solutions, urea, methanol, ethanol, propanol, butanol, ethylene glycol and propylene glycol, and the like).
- water-based earners are approximately neutral pH.
- Suitable carriers include aqueous and oleaginous carries such as, for example, white petrolatum, isopropyl myristate, lanolin or lanolin alcohols, mineral oil, fragrant or essential oil, nasturtium extract oil, sorbitan mono-oleate, propylene glycol, cetylstearyl alcohol
- detergents e.g., polyoxyl stearate or sodium lauryl sulfate
- suitable carriers comprise water-in-oil or oil-in- water emulsions and mixtures of emulsifiers and emollients with solvents such as sucrose stearate, sucrose cocoate, sucrose distearate, mineral oil, propylene glycol, 2-ethyl- 1,3-hexanediol, polyoxypropylene-15-stearyl ether and water.
- emulsions containing water, glycerol stearate, glycerin, mineral oil, synthetic spermaceti, cetyl alcohol, butylparaben, propylparaben and methylparaben are commercially available.
- Preservatives may also be included in the carrier including methylparaben, propylparaben, benzyl alcohol and ethylene diamine tetraacetate salts.
- Well-known flavorings and/or colorants may also be included in the carrier.
- the composition may also include a plasticizer such as glycerol or polyethylene glycol (MW 400 to 20,000).
- the composition of the carrier can be varied so long as it does not interfere significantly with the pharmacological activity of the active ingredients or the viability of the Bacillus cells or spores.
- a therapeutic composition of the present invention may be formulated to be suitable for application in a variety of manners, for example, in a cream for topical application to the skin (e.g., for ringworm or athlete's foot), in a wash for the mouth (e.g., for oral thrush), in a douche for vaginal application (e.g., for vaginitis), in a powder for chaffing ⁇ e.g., for dermatitis), in a liquid for toe nails (e.g., for tinea pedis), in a bath salt or bath powder for treating genital, foot or other tissue infections in a bath, and the like.
- Other formulations will be readily apparent to one skilled in the art and will be discussed more fully in the Specific Examples section, infra.
- the present invention discloses methodologies for treating, reducing, and/or controlling microbial infections in a variety of skin and mucosal membrane tissues using a therapeutic composition or therapeutic article of manufacture of this invention.
- the compositions effectively reduce the bacterial, yeast, fungal and/or viral titer in the treated individual, particularly at the site of application of the topical composition.
- the pathogenic microbial titer in lesions has been demonstrated to be significantly reduced following the topical administration of the therapeutic composition of the present invention to the affected area(s) of the skin or mucous membrane.
- the disclosed methods of treatment also reduce symptoms of pathogenic microbial infection (e.g., pain associated with infected or microbial-caused lesions) and promote more rapid healing than would be found without Bacillus treatment.
- the method of the present invention includes administration of a composition containing the active Bacillus ingredient to a human or animal to treat or prevent microbial (i.e., bacterial, yeast, fungal or viral) infection.
- Administration is preferably to the skin or a mucous membrane using a cream, lotion, gel, oil, ointment, suspension, aerosol spray, powder, semi-solid formulation (e.g., a suppository), or article of manufacture, all formulated so as to contain a therapeutic composition of the present invention using methods well-known in the art.
- Application of the therapeutic composition of the present invention containing the active Bacillus agent effective in preventing or treating a microbial infection, generally consists of one to ten applications of a 10 mg to 10 g concentration of a composition per application, for a time period of one day up to one month. Applications are generally once every twelve hours and up to once every four hours. Preferably, two to four applications of the therapeutic composition per day, of about 0.1 g to 5 g concentration per application, for one to seven days are sufficient to prevent or treat a microbial infection.
- the therapeutic compositions are preferably applied to lesions daily as soon as symptomology (e.g., pain, swelling or inflammation) is detected.
- the specific route, dosage, and timing of the administration will depend, in part, on the particular pathogen and/or condition being treated, as well as the extent of the condition.
- a preferred methodology involves the application of from approximately lxl 0 3 to lxlO 12 viable bacterium or spores per day, preferably from approximately lxlO 5 to lxlO 10 viable bacterium or spores per day, and more preferably about from approximately 5x10 8 to 1x10 viable bacterium or spores per day.
- a prefened method optionally comprises application of a therapeutic composition that additionally contains from approximately 10 mg to 20 g of fructo-oligosaccharide (FOS) per day, preferably from approximately 50 mg to 10 g FOS per day, and more preferably from approximately 150 mg to 5 g of FOS per day, so as to promote the growth of the probiotic Bacillus species over the growth of the pathogenic microbe.
- FOS fructo-oligosaccharide
- one embodiment of the present invention provides for the addition and admixing of a composition of dry Bacillus spores (which may additionally contain soaps, oils, fragrances, salts, and the like bath components) to a prepared bath, followed by contacting the infected tissue(s) to the bath water, as by "taking a bath” in the conventional sense.
- the therapeutic, probiotic Bacillus spores can be packaged in a system with instructions as described herein.
- a typical bath would provide from approximately 1x10 s to lxlO 10 CFU of bacterial cells or spores per bath, and preferably from approximately lxlO 9 to 5xl0 9 CFU of bacterial cells or spores per bath.
- the present invention further discloses a therapeutic system for treating, reducing, and/or controlling microbial infections comprising a container containing a label and a therapeutic composition of the present invention, wherein said label comprises instructions for the use of the therapeutic composition for the treatment of the infection.
- the therapeutic system can comprise one or more unit dosages of a therapeutic composition of the present invention.
- the system can contain bulk quantities of the therapeutic composition.
- the label contains instructions for using the therapeutic composition in either unit dose or in bulk forms as appropriate, and may include information regarding storage of the composition, disease indications, dosages, routes and modes of administration and the like information.
- the system may optionally contain either combined or in separate packages one or more of the following components: FOS, bath salts, soaps and oils (for bathing use), and the like components.
- One particularly preferred system comprises unit dose packages of Bacillus spores for use in combination with a conventional bath salt or bath soap product, together with instructions for using the Bacillus probiotic in a therapeutic method.
- Emu oil an animal-derived lipid, Emu oil, as a "carrying agent" to facilitate the dispersion and penetration of the therapeutic compositions of the present invention through the various coveral and cuticular membranes and tissues, and has been demonstrated to markedly increase the efficacy of anti-microbial and anti- fungal therapies.
- This lipid material is extracted from the Emu (Dromais Novae-Hollandiae), an indigenous bird of Australia and New Zealand.
- Emu oil has been previously described, the uses which are detailed in these documents elaborate only its benefits as an anti-inflammatory agent for arthritis and its uses for cardiovascular health when ingested, which is similar to the use of Omega-3 fish oils to improve high-density lipoprotein (HDL) cholesterol.
- both human and animal beal diseases caused by bacterial and/or mycotic dermatophytes, can be mitigated or prevented, while concomitantly maintaining ECal and cuticular health, by use of a combination of active agents in a therapeutic composition which includes anti-fungal/anti-bacterial agents (e.g., organic molecules, proteins and carbohydrates and or bacterial fermentation products) in combination with Emu oil.
- active agents e.g., organic molecules, proteins and carbohydrates and or bacterial fermentation products
- a therapeutically-effective concentration of Emu oil is combined with the fermentation products of bacteria that have been shown to produce inhibitory metabolites (e.g., Bacillus coagulans) and, optionally, with an antimicrobial agent (e.g., an anti-fungal or antibiotic), in a pharmaceutically-acceptable carrier suitable for administration to the dermal and/or cuticular membranes of an animal.
- inhibitory metabolites e.g., Bacillus coagulans
- an antimicrobial agent e.g., an anti-fungal or antibiotic
- the bacterial strain is a member of the Lactobacillus genus including, but not limited to: Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus salivarius, Lactobacillus delbrukil, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Lactobacillus gaserli, Lactobacillus jensenii and Lactobacillus sporogenes.
- the bacterial strain is a member of the genus Enter ococccus, which include, but are not limited to: Bacillus facium and Enterococccus thermophilus.
- the bacterial strain is a member of the Bifidiobacterium genus, which include, but are not limited to: Bacillus longum, Bacillus infantis, Bacillus bifidus, and Bacillus bifidum.
- the bacterial strain is a member of the genus Bacillus, which include, but are not limited to: Bacillus coagulans,
- the bacterial strain is a member of the genus Pseudomonas, which include, but are not limited to: Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas lindbergii, Pseudomonas cepacia,
- the strain is a member of the genus Sporolactobacillus.
- the bacterial strains which are utilized are members of the genus Micromonospora, Sporolactobacillus, Micrococcus, Berkholderia, Rhodococcus and any of the other bacteria which possess the ability to produce a metabolite that has anti-bacterial, anti- mycotic, or anti-viral activity.
- the aforementioned bacterial supernatant compositions may be combined with an active anti-microbial agent which is a non-microbially-derived compound.
- active anti-microbial agent which is a non-microbially-derived compound.
- non-microbially-derived, anti-microbial compound may include, but are not limited to: a quartenary ammonium chloride, an iodine or iodifer compound (e.g., Betadine®), a phenolic compound, an alcohol compound or tincture (e.g., ethanol, isopropyl, and the like).
- the non-microbially-derived, anti-microbial compound is a systemic anti-fungal compound, including, but not limited to: Amphotericin B, Dapsone, Fluconazole, Flucytosine, Griseofulvin, Itraconazole, Kietoconazole, or Miconazole KI.
- the non-microbially-derived, antimicrobial compound is a topical anti- fungal compound, including, but not limited to: Amphotericin B, Carbol-Fuchsin, Ciclopirox, Clotrimzole, Econazole, Haloprogin, Ketoconazole, Mafenide, Miconazole, Naftifine, Nystatin, Oxiconazole, Silver Sulfadiazine, Sulconazole, Terbinafine, Tioconazole, Tolnafiate, or Undecylenic acid.
- topical anti- fungal compound including, but not limited to: Amphotericin B, Carbol-Fuchsin, Ciclopirox, Clotrimzole, Econazole, Haloprogin, Ketoconazole, Mafenide, Miconazole, Naftifine, Nystatin, Oxiconazole, Silver Sulfadiazine, Sulconazole, Terbinafine, Tioconazole, Tol
- the non-microbially-derived, anti-microbial compound is an anti-fungal vaginal compound, including, but not limited to: Butoconazle, Clotrimazole, Econazole, Gentian Violet, Miconazole, Nystatin, Terconazole, or Tioconazole.
- agents which possess low pH are extremely difficult to mix into soluble compositions with lipophilic agents such as Emu Oil.
- lipophilic agents such as Emu Oil.
- the extracellular products derived from Bacillus coagulans and/or Pseudomonas lindbergii disclosed in the present invention are not lipophilic.
- the hydrophilic extracellular products possess a very low ⁇ i.e., acidic) pH. Stable mixtures of such extracellular products and Emu Oil are difficult to make.
- the mixtures described herein are produced by mixing the extracellular products and Emu Oil and heating the mixture to achieve a stable emulsion.
- the present invention also discloses various articles of manufacture which utilize the beneficial aspects of the present invention by combination of the therapeutic composition with various medical or personal hygiene devices so as to reduce or prevent microbial infections associated with the use of these devices.
- the invention comprises compositions of a Bacillus and/or isolated Bacillus coagulans active agent applied to a solid surface or impregnated into a solid matrix of any device or article of manufacture that is intended to be in contact with skin or a mucous membrane.
- the solid surface is a flexible article than can be worn on or wiped on the skin or mucous membrane.
- the flexible item carrying the Bacillus and/or the isolated active agent when the flexible item carrying the Bacillus and/or the isolated active agent is to be worn on the skin it includes a means for attaching the article to the skin such as, for example, an adhesive layer, inter-engaging hook and pile (z ' .e., Velcro ® ) connectors, or other well-known means of attachment such as ties, snap closures, elastic, buttons and the like.
- a Bacillus and/or isolated Bacillus coagulans active agent are diapers, towelettes (e.g., baby wipes or feminine hygiene towelettes), tampons, dermal patches, adhesive tape, absorbent pads, articles of clothing (e.g., underclothes, sleeping apparel), bath towels, wash cloths, and the like.
- the article may be made of fibrous woven, knitted or non- woven materials, occlusive or non-exclusive films or membranes, synthetic polymer fibers, films, membranes and foams (e.g., nylon, polytetrafluoroethylene (PTFE, such as Teflon ® or Gore-Tex ® ), polystyrene, polycarbonate, polyvinylchioride and polysulphone). All of these forms are well-known within the art and include, for example, knitted or woven fabrics, non-woven fabrics such as felt and batting, fiber balls of cotton, rayon, cellulose or synthetic fibers and the like materials.
- PTFE polytetrafluoroethylene
- the Bacillus and/or Bacillus coagulans isolated active agent can be applied to the solid surface using any of a variety of known methods including, for example, applying a powder, spray drying the probiotic onto the material or soaking the material in a solution containing the probiotic and then using the wetted material or drying the material prior to use.
- Porous material may contain the Bacillus and/or the isolated active agent in the pores or interstices of the solid material.
- the Bacillus and/or the isolated active agent can be attached by adhesion, such as by attachment to an adhesive layer that is then applied to the skin (e.g., in a bandage or dermal patch).
- the Bacillus and/or the isolated active agent can be impregnated into the solid material during the manufacturing process of the flexible article (e.g., added to a synthetic composition before or during the polymerization process).
- the pressure and heat resistance of Bacillus spores makes them particularly suitable for incorporation into the material during manufacturing.
- Any of the solid materials carrying Bacillus and/or the isolated active agent can also be packaged individually or in groups, suitable for holding the treated material using standard packaging materials (e.g., in a shrink wrapper, sealed packet, protective wrapper or dispensing container suitable for holding dry or wet materials).
- the article of manufacture can have applied thereon any of the additional/optional components of a therapeutic composition of this invention, including carriers, salts, FOS, fragrances, and the like.
- prefened methods include a "spray-dry" method in which the material is exposed in a low humidity chamber to an atomized mix containing a liquid composition, where the chamber is subsequently exposed to approximately 80-110°F to dry the liquid, thereby impregnating the material of the article with the components of the composition.
- a typical concentration is from approximately lxlO 5 to lxlO 9 CFU of viable bacterium or spores/in 2 of external surface of fibrous carrier/article material. Following drying, the article is ready for storage in a sterile package, or for direct use.
- Inhibition by Bacillus coagulans was ascertained by placing on the plate approximately 1.5xl0 6 colony forming units (CFU) in 10 ⁇ l of broth or buffer, plated directly in the center of the potato-dextrose plate, with one test locus per plate. The size of each test locus was approximately 8 mm in diameter and a minimum of three tests were performed for each inhibition assay.
- the negative control consisted of a 10 ml volume of sterile saline solution
- the positive control consisted of a 10 ml volume 2% Miconazole (l-[2-(2,4- dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxylmethyl-l, 11-imidazole within an inert cream. The plates were then incubated for approximately 18 hr at 30°C, at which time the zones of inhibition were measured. As designated herein, "excellent inhibition" means the zone was
- Inhibition by Bacillus coagulans was tested by placing on the plate about 1.5x 10 6 colony forming units (CFU) in 10 ⁇ l of broth or buffer, plated directly in the center of the potato-dextrose plate with one test locus of about 8 mm in diameter per plate. A minimum of three tests were performed for each inliibition assay.
- the negative control consisted of a 10 ⁇ l volume of a sterile saline solution, whereas the positive control consisted of a 1 ⁇ l volume of Miconazole cream.
- Inhibition by Bacillus coagulans was subsequently ascertained by placing approximately 1.5x10° CFU of Bacillus coagulans in 10 ⁇ l of broth or buffer, directly in the center of the potato-dextrose plate, with one test locus being approximately 8 mm in diameter per plate. A minimum of three test loci were used for each assay.
- the negative control consisted of a 10 ⁇ l volume of a sterile saline solution, whereas the positive control consisted of a 10 ⁇ l volume of glutaraldehyde.
- the plates were then incubated for approximately about 18 hr at 30°C, at which time the zones of inhibition were measured.
- excellent inhibition means the zone was 10 mm or greater in diameter; and "good inliibition” means the zone was greater than 2 mm in diameter but less than 10 mm in diameter.
- pathogenic enteric bacteria which were shown to be inhibited by Bacillus coagulans activity include, but are not limited to: Staphylococcus aureus; Staphylococcus epidermidus; Streptococcus pyogenes; Pseudomonas aeruginosa; Escherichia coli (entero-hemonagic species); numerous Clostridium species (e.g., Clostridium perfingens, Clostridium botulinum, Clostridium tributrycum, Clostridium sporogenes, and the like);
- Gardnereia vaginails Proponbacterium aenes; Aeromonas hydrophia; Aspergillus species; Proteus species; and Klebsiella species.
- Formulation 1 Bathing Formulation (per bath/dosage) Bacillus coagulans 2.5x10 8 spores (approximately 18 mg)
- Fructo-oligosaccharides 1 gm
- Micro-crystalline cellulose MCC 5 gm Fragrance Trace (B) Formulation 2: Topical Ointment (per ml) Bacillus coagulans extract 100 ⁇ l (see Specific Example C(ii))
- Bacillus coagulans extract 500 ⁇ l (see Specific Example c(ii))
- Bacillus coagulans 1x10 s spores (approximately 8 mg)
- Bacillus coagulans is aerobic and facultative, and is typically cultured at pH 5.7 to 6.8, in a nutrient broth containing up to 2% (by wt) NaCl, although neither NaCl, nor KC1 are required for growth.
- a pH of about 4.0 to about 7.5 is optimum for initiation of sporulation (i.e., the formation of spores).
- the bacteria are optimally grown at 30°C to 45°C, and the spores can withstand pasteurization. Additionally, the bacteria exhibit facultative and hetero trophic growth by utilizing a nitrate or sulfate source.
- Bacillus coagulans can be cultured in a variety of media, although it has been demonstrated that certain growth conditions are more efficacious at producing a culture which yields a high level of sporulation. For example, sporulation is demonstrated to be enhanced if the culture medium includes 10 mg/1 of MgSO sulfate, yielding a ratio of spores to vegetative cells of approximately 80:20. In addition, certain culture conditions produce a bacterial spore which contains a spectrum of metabolic enzymes particularly suited for the present invention ⁇ i.e., production of lactic acid and enzymes for the enhanced probiotic activity and biodegradation). Although the spores produced by these aforementioned culture conditions are preferred, various other compatible culture conditions which produce viable Bacillus coagulans spores may be utilized in the practice of the present invention.
- Suitable media for the culture of Bacillus coagulans include, but are not limited to: PDB (potato dextrose broth); TSB (tryptic soy broth); and NB (nutrient broth), which are all well-known within the field and available from a variety of sources.
- media supplements which contain enzymatic digests of poultry and/or fish tissue, and containing food yeast are particularly prefened.
- a prefened supplement produces a media containing at least 60% protein, and about 20% complex carbohydrates and 6% lipids.
- Media can be obtained from a variety of commercial sources, notably DIFCO (Newark, NJ); BBL (Cockeyesville, MD); Advanced Microbial Systems (Shakopee, MN); and Troy
- the growth medium for Bacillus coagulans comprises a glucose and yeast extract medium which includes the following components: Yeast Extract Powder (Difco) 5.0 g
- Agar (to be added after pH adjustment) 15.0 g The pH of the medium was then adjusted to approximately 6.3 followed by sterilization with
- the trace mineral solution utilized for the analysis of the Bacillus coagulans bacterial strain of the present invention was prepared as per the following composition:
- Hammer bacteria (ATCC No. 31284) was inoculated and grown to a cell density of approximately 1x10 to 1x10 cells/ml in the aforementioned glucose/yeast extract growth medium.
- the bacteria were cultured by utilization of a standard airlift fermentation vessel at 30°C. If sporulation was desired, the acceptable range of MnSO was found to be 1.0 mg/1 to 1.0 g/1.
- the vegetative bacterial cells can actively reproduce up to 65°C, and the spores are stable up to 90°C.
- the Bacillus coagulans Hammer bacterial cells or spores were collected using standard methods (e.g., filtration, centrifugation) and the collected cells and spores may subsequently be lyophilized, spray dried, air dried or frozen. As described herein, the supernatant from the cell culture can be collected and used as an extracellular agent secreted by Bacillus coagulans which possesses anti-microbial activity useful in a formulation of this invention.
- a typical yield obtained from the aforementioned culture methodology is in the range of approximately 10 9 -10 13 viable spores and, more typically, approximately 10-15xl0 10 cells/spores per gram prior to being dried. It should also be noted that the Bacillus coagulans spores, following a drying step, maintain at least 90% viability for up to 7 years when stored at room temperature. Hence, the effective shelf-life of a composition containing Bacillus coagulans Hammer spores at room temperature is approximately 10 years.
- a culture of dried Bacillus coagulans Hammer bacteria (ATCC No. 31284) spores may be prepared as follows. Approximately lxl 0 7 spores were inoculated into one liter of culture medium containing: 24 g (wt./vol.) potato dextrose broth; 10 g of an enzymatic-digest of poultry and fish tissue; 5 g of fructo-oligosaccharides (FOS); and 10 g MnSO 4 . The culture was maintained for 72 hours under a high oxygen environment at 37°C so as to produce a culture having approximately 15xl0 10 cells/gram of culture. The culture was then filtered to remove the liquid culture medium and the resulting bacterial pellet was resuspended in water and lyophilized.
- the lyophilized bacteria were ground to a fine "powder" by use of standard good manufacturing practice (GMP) methodologies.
- the powder is then combined into Formulation 1 or Formulation 4 as described in Specific Example 7.2 to form dry powder compositions.
- GMP standard good manufacturing practice
- the most prefened embodiments of the present invention utilizes Bacillus coagulans in spore, rather than vegetative bacterial form.
- One liter cultures of either Bacillus coagulans or Pseudomonas lindbergii were prepared as follows: (i) cultures of Bacillus coagulans were prepared as described in Example 7.3 using a glucose/yeast extract medium and (ii) cultures of Pseudomonas lindbergii were grow using a potato dextrose medium. In both cases, the initial addition of fructo- oligosacchari.de (FOS) to the culture medium was omitted. The culture was maintained for 5 days as described, at which time FOS was added at a concentration of 5 g/liter, and the culture was continued. Subsequently, 20 ml of carrot pulp was then added at day 7, and the culture was harvested when the culture became saturated ⁇ i.e., no substantial cell division).
- FOS fructo- oligosacchari.de
- the culture was first autoclaved for 30 minutes at 250°F, and then centrifuged at 4000 r.p.m. for 15 mm. The resulting supernatant was collected and subjected to sub-micron filtration, initially with a Buchner funnel through a 0.8 ⁇ m filter. The filtrate was collected and further filtered through a 0.2 ⁇ m Nalge vacuum filter. The resulting final filtrate was then collected (an approximate volume of 900 ml) to form a liquid containing an extracellular product which was to be quantitatively analyzed and utilized in the subsequent inliibition studies.
- Electrophoresis was performed by the method of Laemmli (see Laemmli, 1970. Nature 227: 680-685) and the acrylamide gels were poured in 1 mm cassettes (No vex) and run according to recommendations of the commercial supplier ii.e., 120 volts, for 90 minutes [12% gel] and for 2 hours [16%]). The gels were then silver stained by the method of Blum, et al. (see Blum, et al, 1987. Electrophoresis 8: 93-99). A 12% acrylamide gel was found to best resolved the Pseudomonas lindbergii proteins (see FIG.
- the organic phase was then filtered through 0.2 ⁇ m PVDF filters (Gehnan Acrodisc LC-13) and loaded on an Econosil C-18 10U HPLC column (Altech) in a mobile phase of 20 mM Tris-HCl (pH 7.5). Elution was started after a total of 5 minutes, in a 15 minute linear gradient to 60% acetonitrile (ACN) in water. Elution was continued for 5 minutes in 60% ACN, and the column was then washed and re-equilibrated in
- the molecules which predominate are the proteins, of which there are a total of 20 distinct species in each of the samples. These protein species can be further fractionated by use of ion exchange chromatography, thus allowing additional characterization. Furthermore, there are also numerous pigmented molecules (i.e., molecules which absorb visible light) that are both highly conjugated (based upon their absorbance at high wavelengths) and hydrophobic (based upon their preference for non-polar solvents and retention on the C-18 HPLC column).
- T rubrum was totally inhibited by undiluted supernatant, and 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, and 1:256 serial dilutions, and the organism was 80% inhibited by the compound diluted 1:512 with RPMI medium.
- T. mentagrophytes was totally inhibited by the undiluted supernatant, and 1:2, 1:4, 1:8, and 1:16 serial dilutions, and the organism was 80% inhibited by the supernatant diluted 1 :32 with RPMI medium.
- parapsilosis was totally inhibited by the undiluted supernatant and 1 :2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, and 1:256 serial dilutions, and the organism was 80% inhibited by the supernatant diluted 1:16 with RPMI medium.
- C. albicans was totally inhibited by the undiluted supernatant and a 1 :2 dilution, and the organism was 80%> inhibited by the supernatant diluted 1 :4 with RPMI medium.
- Acremonium sp. was totally inhibited by the undiluted supernatant and was 80%> inhibited by the supematant diluted 1 :2 with RPMI medium.
- Scopulariopis sp. was 80% inhibited by the undiluted supernatant, but was uninhibited by any of the serial dilutions of the supernatant.
- the supernatant showed no inhibitory activity against C. glabrata, C. krusel, or the two Aspergillus species.
- the supernatant was demonstrated to possess marked inhibitory activity, in a wide variety of dilutions, against a majority of the tested organisms.
- the Bacillus coagulans supernatant appeared to be extremely effective against dermatophytes (e.g., Trichophyton sp.), which are a causative organism in many mammalian dermal diseases.
- the liquid containing the extracellular product was formulated into a liquid ointment composition for use in direct application onto a tissue using a dropper, such as would be convenient to treat a fungal infection of the toe nail.
- This liquid ointment was prepared by combining the liquid extracellular product produced above with Emu essential oil in a ratio of approximately 8:2, and trace fragrances were added to produce an aesthetic component.
- a powder, aerosol spray liquid, or aerosol spray powder containing Bacillus coagulans active agent, preferably Bacillus coagulans spores, is applied to diapers by the consumer before use.
- disposable diapers supplied from the manufacture may contain Bacillus coagulans active agent, preferably Bacillus coagulans spores, impregnated into the diaper material where it would be adjacent to the child's skin when in use.
- Bacillus coagulans active agent preferably Bacillus coagulans spores
- Bacillus coagulans spore germination and Bacillus coagulans growth after spore germination produce sufficient anti-fungal, including anti-yeast, activity to inhibit growth of yeast and fungal organisms in the diapers and on the child's skim thus preventing diaper rash or other diaper-associated opportunistic infections.
- the child's skin in the diaper area can be treated with a saturated soft cloth wipe, powder, aerosol spray liquid, aerosol spray powder, lotion, cream or ointment containing Bacillus coagulans active agent.
- the Bacillus coagulans formulation is applied to the child's skin after bathing and/or when the diapers are changed.
- Suitable formulations include a powder of talc and optionally fragrance 10 containing approximately lxl 0 5 to lxl 0 10 Bacillus coagulans spores per gram.
- Other suitable powder formulations contains talc, mineral oil, magnesium carbonate, DMDM, hydantoin, and approximately lxlO 5 to lxlO 10 Bacillus coagulans spores per gram of a corn starch and calcium carbonate powder.
- An aerosol powder that includes an isobutane or other well known propellant made using standard methods is also suitable.
- An aerosol spray may be formulated by combining approximately lxl 0 6 to lxlO 11 Bacillus coagulans spores per gram in isopropyl myristate, about 60% (w/w) SD alcohol 40-B, and isobutane as the propellant using standard methods.
- a manual pump spray containing lxlO 6 to lxlO 11 Bacillus coagulans spores per gram of a neutral aqueous solution with no chemical propellant is also suitable.
- a suitable spray formulation includes alcohol, glycerin, purified water and methylparaben in addition to the Bacillus coagulans probiotic.
- a cream formulation includes aloe vera gel, isopropyl myristate, methylparaben, polysorbate 60, propylparaben, purified water, sorbitan monostearate, sorbitol solution, stearic acid and approximately 1x10 to 1x10 Bacillus coagulans spores per gram.
- Another protective cream contains vitamins A and D equivalent to the concentration found in cod liver oil, cetylpalmitate, cotton seed oil, glycerin, glycerol monostearate, optional fragrance, methylparaben, mineral oil, potassium stearate, propylparaben and approximately lxlO 5 to lxlO 10 Bacillus coagulans spores per gram.
- An ointment contains cod liver oil, lanolin oil, methylparaben, propylparaben, talc, optional fragrance and approximately lxlO 5 to lxlO 10 Bacillus coagulans spores per gram.
- Another ointment formulation includes petrolatum, water, paraffin, propylene glycol, milk protein, cod liver oil, aloe vera gel, optional fragrance, potassium hydroxide, methyl paraben, propyl paraben, vitamins A, D and E and approximately lxl 0 5 to 1x10 Bacillus coagulans spores per gram.
- a soft cloth pad i.e., a baby wipe
- an aqueous solution e.g., water, amphoteric 2, aloe vera gel, DMDM, hydantoin or an aqueous solution of 30% to 70%> alcohol
- aqueous solution e.g., water, amphoteric 2, aloe vera gel, DMDM, hydantoin or an aqueous solution of 30% to 70%> alcohol
- lactic acid-producing microorganisms e.g., Lactobacillus
- Lactobacillus play an important role in the maintenance of a healthy vaginal ecology.
- the traditional methodologies utilized for the administration of these biorational materials do not address the numerous modes of infection of Candida and Gardnerella species, which can cause serious disease.
- gynecologists recommend the use of showers, rather than immersion bathing, to mitigate the probability of developing subsequent vaginal infections due to the associated disturbances of the "normal,” lactic acid-producing vaginal flora.
- VVC vuvo-vaginal candidaiasis
- Candida e.g., primarily Candida albicans
- VVC Yeast infections or vuvo-vaginal candidaiasis
- Candida e.g., primarily Candida albicans
- the market within the United States market for anti-fungal compounds which may be administered to ameliorate this disease is over $700 million dollars per year, with an associated 9-11 % growth rate per annum.
- additional strains of these aforementioned mycotic pathogens are becoming resistant to the commonly utilized anti-fungal compounds (e.g., Ketoconazole, Miconazole, Fluconazole, and the like).
- Lactobacillus acidophilus was not the most common species of Lactobacillus isolated from the vaginas of these women, but rather the most common strains were found to be: Lactobacillus jensenii; Lactobacillus gasserii; Lactobacillus salivarius; and Lactobacillus easel.
- this product must contain a strain of lactic acid-producing bacteria which possesses such characteristics as: (i) long-term shelf-life and viability; (ii) a rapid growth rate (i.e., a rapid doubling-time); and (iv) a highly efficacious production of lactic acid, so as to produce an acidic environment within the vagina.
- bacterial vaginosis is not truly an microorganism-mediated infection, but instead a microecologic condition in which there are dramatic alterations in the endogenous vaginal microflora.
- bacterial vaginosis involves a reduction in the overall number of lactic acid-producing bacterial strains, with a concomitant multi-log population increase in a characteristic set of microflora including, but not limited to: Gardnerella vaginalis, genital anaerobes, and mycoplasmas.
- Gardnerella vaginalis genital anaerobes
- mycoplasmas mycoplasmas.
- these latter microorganisms, along with Streptococci and Coliforms are the same species as those found in chorioamnionitis.
- bacterial vaginosis is also associated with increased concentrations of bacterial endotoxin, proteases, mucinases, sialidases, IgA proteases, and phospholipases A2 and C in the lower reproductive tract.
- Both observational and interventional studies have shown that the presence of bacterial vaginosis in the early stages of pregnancy is associated with pre-term delivery and in later stages of gestation, with miscarriage. These studies suggest that bacterial vaginosis is a direct cause of adverse outcomes in pregnancy, rather than simply being a sunogate marker. Studies suggest that ascending infection or abnormal lower reproductive tract microflora mediate adverse pregnancy outcomes. Similar microbe-host interactions occur in periodontal disease.
- Bacterial vaginosis infections can also be mitigated by lactic acid-producing (i.e., probiotic organisms).
- lactic acid-producing i.e., probiotic organisms
- the cause-and-effect relationship in bacterial vaginosis is due to the reduction of lactic acid-producing bacterial strains with the resulting multi-log increases of to anaerobic microorganisms including, but not limited to, Gardnerella vaginalis.
- Gardnerella vaginalis the results of a recent, 3900- woman study performed in Denmark demonstrated that absence of bacterial vaginosis was directly associated with sufficient vaginal colonization of aerobic lactic acid-producing organisms.
- vaginal supplementation with an effective lactic acid-producing bacterial species will serve to address the imbalance between aerobic lactic acid-producing organisms and the anaerobic species implicated in the etiology of bacterial vaginosis.
- Such vaginal supplementation may either be utilized prophylactically or therapeutically.
- lactic acid-producing bacteria can be incorporated into highly alkaline, bath product compositions. These compositions would prove lethal to almost all other species of lactic acid-producing bacteria including, but not limited to: Lactobacillus, Bifidiobacterium, Enterococccus, and various other stains of vegetative cell bacteria.
- vaginal supplementation remains the major problematic issue of vaginal supplementation and, prior to the present invention, there was a long-felt need for an inoculation strategy which made vaginal lactic acid supplementation incidental.
- the administration of an adequate dose of an effective lactic acid organisms in a bath or shower product would thus address some of the vaginal problems associated with frequent and even occasional bathing, aroma-therapy, sea salt, bath powders, bath gels, bath oils and the like could contain an effective inoculation of lactic acid bacteria for a vaginal application.
- the mechanics of this type of administration may be explained in the following manner.
- the woman After running a warm bath, the woman would add 1-4 ounces of the proposed bath product that contains between approximately lxlO 9 to 2.5xl0 10 vegetative bacterial cells (or spores, depending on the specific bacterial strain which is employed) to the water. The woman would sit in the bath, moving her legs to facilitate vaginal inoculation, for a total of approximately 20 minutes. Subsequently, this treatment could be repeated on the third day (e.g., in cases of acute vuvo-vaginal candidaiasis (VVC) or bacterial vaginitis (BV)), or on a "regular basis" ⁇ i.e., at-least monthly) in order to promote the continued stability of the vaginal ecology and microflora. In addition, this methodology should also prove useful in promoting general dermal health, as some species of lactic acid-producing bacteria are useful in the promotion of healthy skin.
- VVC acute vuvo-vaginal candidaiasis
- BV bacterial vaginit
- strains of bacteria that can be used in a bath or shower products include, Bacillus subtilis, Bacillus laterosporus, Bacillus uniflagellatus. Bacillus pumilus, Bacillus sterothermophilus, Bacillus lentus, Bacillus mycoides, Sporolactobacillus sp. Bacillus licheniformis or any other Bacillus species that out-compete pathogens or has been shown to produce metabolic byproducts that inhibit mycotic or bacterial pathogens.
- An example Bath Salt formulation (per dosage) of the present invention is as follows:
- Fructo-oligosaccharides 1 gm
- MCC Micro-crystalline cellulose
- Bath products including granulated or powdered bubble bath, bath crystals, bath salts, bath oils, powders, aerosol microparticulates and the like, for treatment of vaginal Candida abbicans and/or Candida tropicalis infections may be produced in a variety of formulations which contain Bacillus coagulans vegetative bacterial or (preferably) spores.
- Bacillus coagulans vegetative bacterial or (preferably) spores may be produced in a variety of formulations which contain Bacillus coagulans vegetative bacterial or (preferably) spores.
- bubble baths, bath crystals, bath salts, bath oils and the like are placed in bath water, approximately lxlO 9 Bacillus coagulans spores per ml of an oil-based formulation such as mineral oil, laureth-4, quaternium-18, hectorite, and phenylcarbinol.
- Natural, oil-based formulations, with or without fragrance, containing approximately lxlO 9 Bacillus coagulans spores per ml of an oil which include, but are not limited to, olive oil, grape seed oil, sweet almond oil, geranium oil, grapefruit oil, mandarin oil, peppennint oil, various essential oils (e.g., Rosemary, Lemon, Geranium, Ylang Ylang, Orange, Grapefruit, Fir, Nutmeg, Balsam, Lime, Peppermint, Vanilla, Lavender, Eucalyptus, Almond, Rose, Palmarosa, Olbas, Kukui Nut, Olibanum and the like), as well as other oils, herbs and materials which are well-known for aroma-therapy applications.
- an oil which include, but are not limited to, olive oil, grape seed oil, sweet almond oil, geranium oil, grapefruit oil, mandarin oil, peppennint oil, various essential oils (e.g., Rosemary, Lemon, Ger
- a non-soap emollient cleanser composition includes sodium octoxynol-2 ethane sulfonate solution in water, petrolatum, octoxynol-3, mineral oil or lanolin oil, cocamide MEA, optional fragrance, imidazolidinyl urea, sodium benzoate,
- Hard-milled soaps made by standard methodologies, may also include about lxlO 7 to lxlO 10 Bacillus coagulans spores per gram, due to the fact that the spores can withstand the pressure and heat necessary for soap manufacturing.
- a powder-based composition approximately about lxl 0 9 Bacillus coagulans spores per gm of talc, powdered oatmeal, cornstarch or similar powdered substance are used.
- a soft, cloth towelette soaked in a solution of water, potassium sorbate, disodium EDTA and containing approximately lxlO 6 to lxlO 9 Bacillus coagulans spores per towelette may be utilized to clean the external vaginal area. Additional components to the aforementioned formulation may include DMDM hydantoin, isopropyl myristate, methylparaben, polysorbate 60, propylene glycol, propylparaben or sorbitan stearate. The disposable towelette is used to gently wipe the perivaginal area and is then discarded.
- solid vaginal suppositories or inserts containing approximately 1x10 Bacillus coagulans per inert are utilized for mucosal treatment of Candida abbicans and/or Candida tropicalis infections.
- Such formulations can be made, for example, from a combination of corn starch, lactose, a metal stearate (e.g., magnesium stearate) and povidone.
- a metal stearate e.g., magnesium stearate
- povidone e.g., magnesium stearate
- one to three solid inserts should be used per day while symptoms (e.g., vaginal itch and or whitish discharge) are detected.
- one insert per day for a total of three to seven days, preferably at bedtime, is used.
- an aerosol spray may be formulated by combining approximately lxl 0 ⁇ to lxl 0 11 Bacillus coagulans spores per gm of a carrier mixture which is comprised of isopropyl myristate, approximately about 60% (w/w) SD alcohol 40-B, and isobutane as the propellant.
- a non-aerosol, manual pump spray containing approximately lxlO 5 to lxlO 11 Bacillus coagulans spores per gm of a neutral aqueous solution may also be utilized.
- a suitable spray formulation includes alcohol, glycerin, purified water and methylparaben, in addition to the Bacillus coagulans probiotic microorganism.
- Pseudomonas and or Staphylococcus species i.e., typically Pseudomonas aeruginosa, Staphylococcus epidermidus, Staphylococcus aureus, and the like
- skin allergies e.g., allergic reactions to plant i itants such as poison ivy
- bed sores e.g., diabetic lesions or other types of skin lesions.
- Probiotic formulations containing Bacillus coagulans spores i.e., approximately lxlO 5 to
- probiotic Bacillus coagulans formulations are useful in the prevention of infection with Meticillin-resistant Staphylococcus aureus (MRS A), particularly following injury or invasive surgical procedures.
- MRS A Meticillin-resistant Staphylococcus aureus
- a water-in-oil or oil-in-water emulsion, cream, lotion, powder, aerosol powder, or aerosol spray containing approximately lxl 0 6 to 1x10 Bacillus coagulans spores/ml is used.
- suitable carriers have been previously described herein, and others are well-known within the art.
- the skin is initially cleaned with soap and water and dried thoroughly.
- the Bacillus coagulans-contaix ⁇ ng therapeutic composition is then applied to the skin, ensuring that the composition is applied to the areas between the toes, under the breasts, under the arms, or any other areas where the skin may become moist or exhibit frictional chafing or abrasion.
- the skin may be cleansed with a probiotic formulation such as described herein.
- Ringworm (tinea versicolor) is caused by localized infections of the skin of the trunk and neck by dermatophyte fungus which colonizes the outer layer of the skin resulting in generally circular patches of white, brown or pink flaking skin that are often itchy.
- dermatophyte fungus which colonizes the outer layer of the skin resulting in generally circular patches of white, brown or pink flaking skin that are often itchy.
- the affected area and a surrounding approximately 1 to 10 cm area is treated twice daily with a cream or lotion containing 10%> by weight Bacillus coagulans spores.
- Suitable carriers are described herein, preferably containing approximately lxlO 5 to lxl 0 10 Bacillus coagulans spores/ml of carrier.
- tinea cruris i.e., "jock itch”
- a powder containing approximately lxlO 7 to lxlO 9 Bacillus coagulans spores/ml of colloidal silicon dioxide, isopropyl myristate, talc and optional fragrance is applied to the groin area to provide relief of itching, chafing, burning rash and irritation. Treatment is twice daily, generally after bathing and at bedtime, until symptoms are no longer detected.
- Clothing particularly underclothes and nightclothes that come in contact with the trunk and neck are sprayed with an aerosol containing about 1% to about 20%> Bacillus coagulans active agent in a suitable carrier such as described herein, so as to ameliorate the spread of the infection to additional areas of the body.
- lactic acid-producing bacteria e.g., Bacillus coagulans and Pseudomonas lindbergii
- Bacillus coagulans and Pseudomonas lindbergii have been shown to produce extracellular products that are anti-fungal in nature although all of the products that have come from these bacteria are a result of the purification of a specific active analog such as a protein, carbohydrate or organic molecule to form a new anti-fungal compound. It has been suggested that the use of a single active agent contributes to resistant species of pathogenic fungi and as a result new generations of anti-fungal compounds must be discovered in order to control these new developing species.
- a bacterial supernatant in its crude or in a semi- refined state my be more effective in topical applications and may, in fact, decrease the rate of anti-fungal resistance by providing a more complex killing mechanism that is more difficult to overcome than a single chemical agent or analog.
- Emu oil as a "carrier" in the therapeutic compositions of the present invention markedly enhances efficacy in the prevention and/or therapeutic treatment of fungal or bacterial infections of the dermis and cuticle in both humans and animals.
- These therapeutic compositions are comprised of the fermentation products of specific bacterial strains and, optionally, a commercially available antibiotic or anti-fungal agent in combination with an effective amount of Emu oil in a pharmaceutically acceptable cater suitable for administration to the dermal and/or cuticular membranes of a human or animal.
- the final form of the therapeutic composition may include, but is not limited to: a stabilized gel, a lotion, a cream, a semi-solid roll-on stick, a fluid, an aerosol, a spray powder, or an emulsion.
- the overall efficacy of the therapeutic compositions of the present invention is relative to the concentration of Emu oil which is utilized in the formulation. Specifically, it has been observed that higher percentages of Emu oil is more effective than lower percentages.
- the range of Emu oil used in a topical therapeutic composition of the present invention ranges from approximately 0.5% to 99.9 %, with a more preferable range being between approximately 10% to 75%, and the most preferable range being between approximately 25%> to 60%.
- the 0.5% to 99.9%> ultimate effective range for Emu oil concentration is due to the very small concentrations of antimicrobial compounds which are typically used in the therapeutic compositions of the present invention.
- the anti-fungal agent in a dermal application, generally comprises only 2% of the total formulation.
- these aforementioned therapeutic compositions of the present invention may also be utilized in combination with other anti-fungal agents, including, but not limited to: Fluconazole, Intraconazole, Ketoconazole, Tolnaftate, Lamasil, Quaternary Ammonium Chlorides, Phenolics, lodiphers, and the like.
- other materials e.g., Titanium oxide
- to enhance the whitening of the toe or finger nail may also be used.
- a therapeutic composition of the present invention containing bacterial supernatant derived from Bacillus coagulans, was used to mitigate the human fungal infection, Onychomycosis.
- One ml of the aforementioned therapeutic composition was applied after bathing to each infected nail. Treatment resulted in a change in the green-to- yellow color of the nail within 10 days, in all individuals studied. In addition, within the first 7 days, the detritus under the nail sloughed-off and the thickness of the nail (one of the clinical manifestations of the disease) began to subside.
- Emu oil possess the ability to rehydrate skin cells in a way that promotes the growth of new cells. Similarly, it is quite possible that Emu oil acts in a similar manner in human nail and cuticular tissues.
- a therapeutic composition of the present invention containing bacterial supernatant derived from Bacillus coagulans, was also utilized to treat cases of diaper rash which were complicated with bacterial or fungal infections . Immediate (i.e., approximately 18 hours) relief of the dermal inflammation and redness was achieved, and all of the infections were completely ameliorated within 48 hours.
- equine hoof diseases e.g., White Line disease, Hoof Thrush, Drop Sole, and even Clubbed Foot
- Various equine hoof diseases have also responded to the use of therapeutic compositions of the present invention, containing bacterial supernatant derived from Bacillus coagulans, in the same manner as Onychomycosis in humans.
- Emu oil may also function to rehydrate and stimulate new cell growth within animal hooves and other cuticular materials.
- Staphylococcus epidermidis of a blocked sweat or sebaceous gland cause pustules, boils, abscesses, styes or carbuncles. These superficial skin infections may also be accompanied by a blistering rash (particularly in babies), due to bacterial toxins released by the Staphylococcus species.
- Bacillus coagulans spores/ml may be used.
- An exemplary topical gel is prepared by mixing together equal volumes of propylene glycol and water, 1% by weight hydroxypropyl cellulose (MW of 100,000 to 1,000,000 Daltons) and lyophilized Bacillus coagulans culture to a final concentration of approximately lxlO 6 to lxl 0 9 Bacillus coagulans spores/ml of the combination, and allowing the stined mixture to sit for 3 to 5 days to form a gel.
- Other formulations are also presented herein.
- the Bacillus coagulans-containing emulsion, cream, lotion, or gel is applied to the area of the skin showing superficial skin infections (e.g., pustules, boils, abscesses, styes or carbuncles) or rash and gently rubbed into the skin and allowed to air-dry.
- Applications are at- least once per day, and preferably two to three times per day (e.g., morning and night), or after each washing of the infected area for those areas which are washed frequently (e.g., the hands or diaper area). Applications are continued until skin inflammation has subsided and the skin appears normal to the observer. In cases where scab formation has occurred in the infected area, once daily applications are continued until the scabs are no longer present.
- a cleanser containing Bacillus coagulans active ingredient obtained from a supernatant of bacterial culture is applied daily as a skin care product for removing excess dirt and oil and for preventing opportunistic infection of the skin.
- a suitable cleanser includes bentonite, cocoamphodipropionate, optional fragrance, glycerin, iron oxides, magnesium silicate, sodium borohydride, sodium chloride, sodium cocoate, sodium tallowate, talc, tetrasodium EDTA, titanium dioxide, trisodium EDTA, water and approximately 1% to about 20%> (v/v) of an aqueous supernatant or filtrate of a Bacillus coagulans culture grown to saturation.
- a similar cleanser particularly for sensitive skin, includes approximately 30% to 50%> colloidal oatmeal, suspended in a base of water, glycerin, distearyldimonium chloride, petrolatum, isopropyl palmitate, cetyl alcohol, dimethicone, sodium chloride, adjusted to pH about 7.0, and containing approximately 5% to about 50% (v/v) of an aqueous supernatant or filtrate of a Bacillus coagulans culture grown to saturation.
- the skin may be cleansed using any well-known cleanser and then a cream containing an active ingredient derived from a Bacillus coagulans or Pseudomonas lindbergii culture supernatant or filtrate is applied to the skin in a thin film about once every two days to about three times daily as needed.
- a suitable cream includes approximately 10%) to 12% alcohol (v/v), bentonite, optional fragrance, iron oxides, potassium hydroxide, propylene glycol, titanium dioxide, purified water and approximately 0.5%> to 60% (v/v) of an aqueous supernatant or filtrate of a Bacillus coagulans or Pseudomonas lindbergii culture grown to saturation.
- the above formulation is suited for treating acne caused by Propionibacterium acne and by Staphylococcus epidermidis. 7.12 Treatment of Herpes simplex I & II and Herpes zoster Infections
- Herpes simplex viral infections can also cause painful finger or toe swelling (i.e., Herpetic Whitlow). Both types of Herpes simplex lesions or Whitlow can be treated with a cream, lotion or gel ointment containing approximately lxlO 7 to lxlO 10 Bacillus coagulans spores/ml.
- a soothing emollient lip balm contains allantoin, petrolatum,
- the lip balm may further include a sunscreen (e.g., padimate O).
- An alternative emollient lip balm contains the same base ingredients mixed to form an emulsion with approximately 0.5% to 20% (v/v) of an aqueous supernatant or filtrate of a Bacillus coagulans culture grown to saturation.
- the lip balm is then applied to the lips and affected area to form a light film as a prophylactic when prodromal symptoms are felt (e.g., tingling, itching, burning) or when a lesion is visible.
- the lip balm should be applied as often as required (e.g., every hour when a lesion is present) and generally once per day at bedtime.
- the Bacillus coagulans spores or extracellular agent in culture supernatant or filtrate may be formulated into a semisolid lip balm containing approximately 20% to 40% white petrolatum, wax paraffin, mineral oil, isopropyl lanolate, camphor, lanolin, isopropyl myristate, cetyl alcohol, camuba wax, methylparaben, propylparaben, titanium dioxide and optionally fragrance and coloring agents.
- a cream or ointment is formulated using standard methods as described herein containing approximately lxl 0 7 to 1x10 Bacillus coagulans spores/ml and/or approximately 0.5%o to 20% (v/v) of an aqueous supernatant or filtrate of a Bacillus coagulans culture grown to saturation.
- the cream or ointment is applied at least twice daily as needed.
- an aqueous formulation that includes approximately lxl 0 5 to lxl 0 8 Bacillus coagulans spores/ml and/or approximately ' 0.1%) to 15% (v/v) of an aqueous supernatant or filtrate of a Bacillus coagulans or Pseudomonas lindbergii culture grown to saturation, is utilized.
- the spores and/or supernatant is added to a sterile aqueous solution containing approximately 5% to 50%> glycerin (v/v), approximately 0.1 % to 5%> propylene glycol (v/v), and sodium stannate or sodium chloride.
- An alternative formulation includes approximately lxl 0 5 to lxl 0 8 Bacillus coagulans spores/ml and/or approximately 0.1%> to 15% (v/v) of an aqueous supernatant or filtrate of a Bacillus coagulans or Pseudomonas lindbergii culture grown to saturation in a sterile aqueous solution of approximately 0.5% to 25%> glycerin (v/v), approximately 5%> to 10%) alcohol (v/v), and polysorbate 20.
- the user tilts the head sideways and about 3 to 10 drops of the aforementioned ear formulation is added to the ear using a standard dropper applicator, without having the applicator actually enter the external ear canal.
- the head is kept tilted for several minutes or, alternately, the ear may be lightly plugged with a wad of cotton so as to allow the solution to remain in the ear for up to 15 minutes. Then the head is then tilted, and excess solution is allowed to drain from the ear. Gentle washing with an ear syringe containing warm water may also be utilized to remove the excess formulation.
- the probiotic solution can be applied occasionally or daily for up to approximately five days in-total.
- the accompanying instructions indicate that a physician should be consulted if there is drainage, discharge, rash, severe irritation in the ear, or if the patient experiences dizziness.
- the -feet are washed with soap and water, dried thoroughly and a powder, cream, lotion, ointment or gel, such as those described in the above examples is applied to the entire foot area.
- the formulation includes approximately 1x10 to 1x10 Bacillus coagulans spores/ml and or approximately 0.5% to 20%> Bacillus coagulans supernatant or filtrate of a Bacillus coagulans or Pseudomonas lindbergii culture grown to saturation. Daily treatments are continued as needed.
- athlete's foot may be prevented or treated by using a standard insole insert (e.g., a fabric, fiber or synthetic foam) having sprayed on the surface or impregnated therein with the Bacillus coagulans probiotic or extracellular anti-fungal product.
- a standard insole insert e.g., a fabric, fiber or synthetic foam
- Such treated insoles may be worn daily for up to two to three months, after which they are discarded and replaced with fresh treated insoles.
- the final form e.g., stabilized gel, cream, emulsification, and the like
- the final form e.g., stabilized gel, cream, emulsification, and the like
- the final form which is selected for the therapeutic composition is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the embodiments described herein.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2382840A CA2382840C (en) | 1999-08-26 | 2000-08-25 | Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereof |
AT00961363T ATE308988T1 (en) | 1999-08-26 | 2000-08-25 | IMPROVED TOPICAL COMPOSITIONS CONTAINING EXTRACELLULAR PROBIOTIC BACTERIA PRODUCTS AND USES THEREOF |
JP2001518064A JP2003507428A (en) | 1999-08-26 | 2000-08-25 | Improved topical compositions comprising commensal bacteria, spores and extracellular products, and uses thereof |
DE60023919T DE60023919T2 (en) | 1999-08-26 | 2000-08-25 | IMPROVED TOPICAL COMPOSITIONS WITH EXTRACELLULAR PRODUCTS OF PROBIOTIC BACTERIA AND USES THEREOF |
EP00961363A EP1212069B1 (en) | 1999-08-26 | 2000-08-25 | Improved topical compositions containing extracellular products of probiotic bacteria and uses thereof |
AU73324/00A AU783418B2 (en) | 1999-08-26 | 2000-08-25 | Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/383,975 US6645506B1 (en) | 1997-04-18 | 1999-08-26 | Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil |
US09/383,975 | 1999-08-26 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001013927A2 WO2001013927A2 (en) | 2001-03-01 |
WO2001013927A3 WO2001013927A3 (en) | 2001-08-30 |
WO2001013927A9 true WO2001013927A9 (en) | 2002-07-11 |
Family
ID=23515538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/023300 WO2001013927A2 (en) | 1999-08-26 | 2000-08-25 | Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereof |
Country Status (9)
Country | Link |
---|---|
US (6) | US6645506B1 (en) |
EP (2) | EP1632239A1 (en) |
JP (1) | JP2003507428A (en) |
AT (1) | ATE308988T1 (en) |
AU (1) | AU783418B2 (en) |
CA (1) | CA2382840C (en) |
DE (1) | DE60023919T2 (en) |
ES (1) | ES2256036T3 (en) |
WO (1) | WO2001013927A2 (en) |
Families Citing this family (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2020959C1 (en) * | 1991-10-21 | 1994-10-15 | Игорь Дмитриевич Поляков | Vaccine for prevention and treatment of dermatophytoses in animals |
ATE493139T1 (en) * | 1997-04-18 | 2011-01-15 | Ganeden Biotech Inc | SURFACE USE OF PROBIOTIC BACILLUS SPORES TO PREVENT OR CONTROL MICROBIAL INFECTIONS |
US6645506B1 (en) * | 1997-04-18 | 2003-11-11 | Ganeden Biotech, Inc. | Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil |
US6716435B1 (en) * | 1997-04-18 | 2004-04-06 | Ganeden Biotech, Inc. | Absorbent product containing absorbent structure and Bacillus coagulans |
US7767203B2 (en) | 1998-08-07 | 2010-08-03 | Ganeden Biotech, Inc. | Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption |
US6461607B1 (en) * | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
ATE270558T1 (en) * | 1999-08-26 | 2004-07-15 | Ganeden Biotech Inc | USE OF EMU OIL AS A CARRIER FOR FUNGICIDES, ANTIBACTERIAL AND ANTIVIRAL MEDICATIONS |
AU783905B2 (en) * | 1999-08-26 | 2005-12-22 | Ganeden Biotech, Inc. | Use of emu oil carrier for antifungal, antibacterial, and antiviral medications |
US6849256B1 (en) | 1999-11-08 | 2005-02-01 | Ganeden Biotech Incorporated | Inhibition of pathogens by probiotic bacteria |
EP1110555A1 (en) * | 1999-12-22 | 2001-06-27 | Societe Des Produits Nestle S.A. | Antiadhesive agent for the pathogen flora of the skin |
CA2424607C (en) * | 2000-10-06 | 2013-01-15 | Societe Des Produits Nestle S.A. | Use of probiotic lactic acid bacteria for balancing the skin's immune system |
JP2004517127A (en) | 2000-12-21 | 2004-06-10 | ネクター セラピューティックス | Pulmonary delivery of polyene antifungals |
US20070190591A1 (en) * | 2001-05-02 | 2007-08-16 | Grech Nigel M | Microbial compositions and methods of use in water |
WO2003039260A2 (en) * | 2001-11-05 | 2003-05-15 | Ganeden Biotech Inc | Probiotic compositions |
US6878373B2 (en) | 2001-12-03 | 2005-04-12 | Micropure Technologies, Inc. | Probiotic composition containing Bacillus cereus RRRL B-30535 |
US7182943B2 (en) * | 2002-05-15 | 2007-02-27 | UNIVERSITé LAVAL | Method and system for modulation of microbial cell characteristics |
US7632525B2 (en) * | 2002-06-25 | 2009-12-15 | Wm. Wrigley Jr. Company | Breath freshening and oral cleansing product with magnolia bark extract in combination with surface active agents |
US7595065B2 (en) * | 2002-06-25 | 2009-09-29 | Wm. Wrigley Jr. Company | Breath freshening and oral cleansing products with synergistic combinations of magnolia bark extract and essential oils |
US7347985B2 (en) * | 2002-06-25 | 2008-03-25 | Wm. Wrigley Jr. Company | Breath freshening and oral cleansing product with magnolia bark extract |
AU2003280960A1 (en) * | 2002-07-15 | 2004-02-02 | Alcon, Inc. | Pharmaceutical compositions for otic use |
US20040265291A1 (en) * | 2003-01-24 | 2004-12-30 | Flora Technology Inc. | Compositions and methods for restoring bacterial flora |
US7052715B2 (en) * | 2003-04-11 | 2006-05-30 | All Natural Fmg, Inc. | Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof |
US20050019379A1 (en) * | 2003-07-22 | 2005-01-27 | Kimberly-Clark Worldwide, Inc. | Wipe and methods for improving skin health |
US7749509B2 (en) * | 2003-08-29 | 2010-07-06 | Cobb And Company, Llp | Treatment of autism using probiotic composition |
US7759105B2 (en) * | 2003-08-29 | 2010-07-20 | Cobb & Company, Llp | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions |
US7731976B2 (en) * | 2003-08-29 | 2010-06-08 | Cobb And Company, Llp | Treatment of irritable bowel syndrome using probiotic composition |
US8192733B2 (en) | 2003-08-29 | 2012-06-05 | Cobb & Associates | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions |
EP1506781B1 (en) * | 2003-11-03 | 2005-02-23 | Peter-Hansen Volkmann | Vaginal care composition |
EP1706128B1 (en) | 2003-12-08 | 2010-07-21 | CPEX Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for insulin treatment |
US20050226947A1 (en) * | 2004-02-04 | 2005-10-13 | Dale Kern | Agents for sequestering serum aging factors and uses therefore |
WO2005091933A2 (en) * | 2004-03-04 | 2005-10-06 | E-L Management Corporation | Skin treatment method with lactobacillus extract |
US20080107751A1 (en) * | 2004-03-10 | 2008-05-08 | Jeff Hudnall | Antimicrobial Wax Composition for Wax Therapy |
US20050244402A1 (en) * | 2004-04-30 | 2005-11-03 | Villanueva Julie M | Absorption of pain-causing agents |
US7854927B2 (en) * | 2004-05-11 | 2010-12-21 | Ganeden Biotech, Inc. | Methods and compositions for the dietary management of autoimmune disorders |
US7446904B2 (en) * | 2004-05-28 | 2008-11-04 | Infoprint Solutions Company, Llc | Methods and apparatus for generating dither mask through interpolation between preferred patterns |
US7252846B2 (en) | 2004-05-28 | 2007-08-07 | Raied Dinno | Topical composition and method for the treatment and prophylaxis of dermal irritations |
FR2872047B1 (en) * | 2004-06-23 | 2007-06-15 | Oreal | COMPOSITION FOR SENSITIVE SKINS COMBINING MINERAL AND PROBIOTIC CATION (S) |
MXPA06015184A (en) * | 2004-06-23 | 2007-11-22 | Nestec Sa | Method and compositions useful for preventing and/or treating sensitive and/or dry skin. |
US7704522B2 (en) * | 2004-09-08 | 2010-04-27 | Clyde Morgan | Topical medicament |
MX2007004135A (en) * | 2004-10-04 | 2007-06-15 | Oreal | Cosmetic and/or dermatological composition for sensitive skins. |
US8092793B2 (en) * | 2004-12-15 | 2012-01-10 | Qingdao East Sea Pharmaceuticals, Ltd. | Treating inflammatory bowel disease with live bacteria |
WO2006076780A1 (en) * | 2004-12-17 | 2006-07-27 | Gielen Cornelis | Use of non-pathogenic bacterial strains in cleaning and milking an animal |
US20060147507A1 (en) * | 2005-01-04 | 2006-07-06 | Marie Cammarata | Hot flash treatment system |
EP1928247A4 (en) * | 2005-04-20 | 2009-10-28 | Health Enhancement Products In | Composition and use of phyto-percolate for treatment of disease |
WO2006115430A1 (en) * | 2005-04-28 | 2006-11-02 | Irina Grigorievna Osipova | Irilis biopreparation based on bacillus-strain bacteria, bacillus subtilis and bacillus licheniformis contained therein |
DE102005020457A1 (en) * | 2005-04-29 | 2006-11-02 | Westfaliasurge Gmbh | Use of non-pathogenic sporulating bacteria for inhibiting the growth of infectious germs on the udder and/or teat of a lactating mammal |
FR2889057B1 (en) * | 2005-08-01 | 2008-07-18 | Oreal | COSMETIC AND / OR DERMATOLOGICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF SENSITIVE OR DRY SKINS |
WO2007038466A2 (en) * | 2005-09-27 | 2007-04-05 | Cobb & Company | Treatment of bipolar disorder utilizing anti-fungal compositions |
JP2009512729A (en) * | 2005-10-24 | 2009-03-26 | スタヴァル ファーマ リミテッド | Methods for treating, controlling and killing fungi and bacteria |
US20080220103A1 (en) * | 2005-10-24 | 2008-09-11 | Jay Birnbaum | Method for treating/controlling/killing fungi and bacteria on living animals |
WO2007077210A1 (en) * | 2006-01-04 | 2007-07-12 | Wikstroem Maude | Probiotic oral health promoting product |
US20070238145A1 (en) * | 2006-02-21 | 2007-10-11 | Cote Mindy A | Phenotypic engineering of spores |
CN101095698B (en) * | 2006-06-26 | 2010-12-01 | 青岛东海药业有限公司 | Use of Clostridium Butyricum for preventing and treating foetid faeces toxin syndrome and disease |
US20080031979A1 (en) * | 2006-08-04 | 2008-02-07 | Claude Saliou | Use of extracts for the treatment of viral disorders |
CN103122327B (en) | 2006-08-11 | 2015-11-18 | 诺维信生物股份有限公司 | Bacterial cultures and the composition comprising bacterial cultures |
US7858126B2 (en) | 2006-08-31 | 2010-12-28 | Trinity Laboratories Inc. | Derivatives of sandalwood oil and santalols for treating cold sores and herpes |
US20080075680A1 (en) * | 2006-09-27 | 2008-03-27 | Chen Jonathan Y | Culture of microorganisms endogenous to plants and products thereof |
US20080107699A1 (en) * | 2006-10-25 | 2008-05-08 | Mark Spigelman | Method of using topical probiotics for the inhibition of surface contamination by a pathogenic microorganism and composition therefor |
CN101134052A (en) * | 2006-11-17 | 2008-03-05 | 青岛东海药业有限公司 | Application of clostridium butyricum, condensate bacillus and bifidobacteria in the preparation of medicament for preventing and treating mouth ulcer |
WO2008070602A2 (en) * | 2006-12-04 | 2008-06-12 | Smithkline Beecham Corporation | Topical pharmaceutical composition |
FR2914189A1 (en) * | 2007-03-26 | 2008-10-03 | Oreal | USE OF A LIPOPOLYSACCHARIDE FRACTION OF VITREOSCILLA FILIFORMIS AS AGENT STIMULATING THE SYNTHESIS OF ANTIMICROBIAL PEPTIDES OF THE SKIN. |
EA016247B1 (en) | 2007-04-19 | 2012-03-30 | Мэри Кэй Инк. | Topical composition for reducing dark circles under the eye puffy eyes and skin swelling and method for applying thereof |
FR2915388B1 (en) | 2007-04-27 | 2010-12-24 | Oreal | COSMETIC WATER SOLUBLE FILM |
TW200904340A (en) | 2007-05-11 | 2009-02-01 | Mannatech Inc | Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same |
WO2008153377A1 (en) | 2007-06-15 | 2008-12-18 | N.V. Nutricia | Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide |
FR2919501B1 (en) * | 2007-08-02 | 2010-12-31 | Oreal | USE OF HESPERIDINE OR ONE OF ITS DERIVATIVES FOR THE PREVENTION AND / OR TREATMENT OF RELEASED SKINS |
JP5520223B2 (en) | 2007-08-29 | 2014-06-11 | ガネーデン バイオテック インコーポレイテッド | Baked products |
FR2920304B1 (en) | 2007-09-04 | 2010-06-25 | Oreal | COSMETIC USE OF LYSAT BIFIDOBACTERIUM SPECIES FOR THE TREATMENT OF DROUGHT. |
CN101815502B (en) * | 2007-09-04 | 2013-10-09 | 欧莱雅 | Use of a combination of hesperidin and of a microorganism for influencing the barrier function of the skin |
FR2920305B1 (en) | 2007-09-04 | 2010-07-30 | Oreal | USE OF A SPECIFIC BIFIDOBACTERIUM LYSATE FOR THE TREATMENT OF SENSITIVE SKINS. |
CA2702668C (en) * | 2007-10-16 | 2015-12-29 | Ganeden Biotech, Inc. | Beverage compositions |
US20090107007A1 (en) * | 2007-10-31 | 2009-04-30 | Mitchellace, Inc. | Insole with included aloe extract |
US9314524B2 (en) * | 2007-12-31 | 2016-04-19 | Calla Therapeutics Llc | Topical formulations of Flucytosine |
WO2009099562A2 (en) * | 2008-01-30 | 2009-08-13 | Ganeden Biotech, Inc. | Compositions and methods for cleaning surfaces |
US20090246153A1 (en) * | 2008-03-28 | 2009-10-01 | Nu Skin International, Inc. | Cosmetic compositions for the inhibition of reactive oxygen species |
US20090246152A1 (en) * | 2008-03-28 | 2009-10-01 | Nu Skin International, Inc. | Naractin compositions for the inhibition of reactive oxygen species |
US7788209B2 (en) * | 2008-05-05 | 2010-08-31 | United Technologies Corporation | Hybrid fault reasoning and guided troubleshooting system that uses case-based reasoning and model-based reasoning |
FR2938437B1 (en) * | 2008-11-19 | 2020-03-27 | Société des Produits Nestlé S.A. | COSMETIC USE OF MICROORGANISM FOR THE TREATMENT OF OILY SKIN |
US11028454B2 (en) * | 2008-09-24 | 2021-06-08 | Resilux | Incorporation of thermo-resistant and/or pressure-resistant organisms in materials |
US20100160224A1 (en) * | 2008-10-14 | 2010-06-24 | David Thomas | Shelf-stable consumable compositions containing probiotic-mimicking elements and methods of preparing and using the same |
WO2010045541A1 (en) | 2008-10-16 | 2010-04-22 | Ganeden Biotech, Inc. | Probiotic grain-based compositions |
FR2942719B1 (en) | 2009-03-04 | 2011-08-19 | Oreal | USE OF PROBIOTIC MICROORGANISMS TO LIMIT SKIN IRRITATION |
EP2424550B1 (en) | 2009-04-29 | 2017-06-07 | Ganeden Biotech, Inc. | Bacterial cell membrane formulation |
US8506952B2 (en) * | 2009-07-03 | 2013-08-13 | James Madison Innovations, Inc. | Probiotic compositions and process thereof |
FR2954140A1 (en) * | 2009-12-17 | 2011-06-24 | Oreal | COSMETIC OR DERMATOLOGICAL COMPOSITIONS BASED ON BACTERIOCINS AND PREBIOTICS |
EP2338331A1 (en) * | 2009-12-22 | 2011-06-29 | Research Center Pharmaceutical Engineering GmbH | Methods and compositions for biologically controlling microbial growth on clean room equipment |
US20110229446A1 (en) * | 2010-03-02 | 2011-09-22 | Roman Stephen B | Method and composition to relieve sexual discomfort and improve vaginal health |
CN103037877A (en) * | 2010-03-12 | 2013-04-10 | 可尔必思株式会社 | Agent for controlling the increase and decrease of lactobacillus bifidus in colon |
US9301982B2 (en) | 2010-04-14 | 2016-04-05 | Ganeden Biotech, Inc. | Probiotic confection and lipid compositions |
JP2013529642A (en) * | 2010-06-24 | 2013-07-22 | ノボザイムス バイオロジカルズ,インコーポレイティド | Methods and compositions for reducing body odor |
EP2608678A1 (en) * | 2010-08-25 | 2013-07-03 | Tate & Lyle Ingredients Americas LLC | Synbiotic product |
WO2012031186A1 (en) | 2010-09-03 | 2012-03-08 | Wisconsin Pharmacal Company, Llc. | Prebiotic suppositories |
FR2968991B1 (en) * | 2010-12-17 | 2013-01-11 | Oreal | "USE OF STABLE MICROBIAL POPULATION TO PREVENT AND / OR TREAT THE DISORDERS OF FRAGILIZED OR DAMAGED LIP" |
EP2654432B1 (en) * | 2010-12-22 | 2017-02-08 | Roombiotic GmbH | Volatile organic compounds from bacterial antagonists for controlling microbial growth |
PL2675891T3 (en) | 2011-02-15 | 2019-03-29 | Novozymes Biologicals, Inc. | Mitigation of odor in cleaning machines and cleaning processes |
US11235008B2 (en) | 2011-03-31 | 2022-02-01 | Ganeden Biotech, Inc. | Probiotic sports nutrition compositions |
US20120255334A1 (en) * | 2011-04-08 | 2012-10-11 | Stephen Gans | Soluble organic fertilizer |
US20120308490A1 (en) * | 2011-06-06 | 2012-12-06 | Abr Consulting S.R.L. | Method of obtaining a preparation of biological origin for oral hygiene to prevent the onset of tooth decay |
US9004374B1 (en) * | 2011-07-20 | 2015-04-14 | Stephen Gans | Irrigation method using thixotropic materials |
CN103468688B (en) * | 2012-01-05 | 2016-04-06 | 集美大学 | Aeromonas hydrophila is fit and screening method and application |
WO2013159029A1 (en) * | 2012-04-20 | 2013-10-24 | Hennepin Life Sciences | Compositions for topical treatment of microbial infections |
GB201312713D0 (en) | 2013-03-22 | 2013-08-28 | Weaver Connie M | Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption |
US10010704B2 (en) | 2013-08-23 | 2018-07-03 | Elwha Llc | Systems, methods, and devices for delivering treatment to a skin surface |
US9811641B2 (en) | 2013-08-23 | 2017-11-07 | Elwha Llc | Modifying a cosmetic product based on a microbe profile |
US9390312B2 (en) | 2013-08-23 | 2016-07-12 | Elwha Llc | Systems, methods, and devices for assessing microbiota of skin |
US9456777B2 (en) | 2013-08-23 | 2016-10-04 | Elwha Llc | Systems, methods, and devices for assessing microbiota of skin |
US10152529B2 (en) | 2013-08-23 | 2018-12-11 | Elwha Llc | Systems and methods for generating a treatment map |
US9805171B2 (en) | 2013-08-23 | 2017-10-31 | Elwha Llc | Modifying a cosmetic product based on a microbe profile |
US9557331B2 (en) | 2013-08-23 | 2017-01-31 | Elwha Llc | Systems, methods, and devices for assessing microbiota of skin |
US8883747B1 (en) | 2013-10-09 | 2014-11-11 | Craig W. Carver | Topical antifungal compositions and methods of use thereof |
US9596861B2 (en) | 2013-12-24 | 2017-03-21 | Sami Labs Limited | Method of producing partially purified extracellular metabolite products from Bacillus coagulans and biological applications thereof |
ES2821813T3 (en) * | 2014-03-31 | 2021-04-27 | Lubrizol Advanced Mat Inc | Fermentation extract of a bacterial strain to increase adiponectin levels |
CN104946550A (en) * | 2014-05-12 | 2015-09-30 | 山东黎昊源生物工程有限公司 | Leaf-protection biological strain repair agent |
CA2948832A1 (en) | 2014-05-13 | 2015-11-19 | Microbial Discovery Group, Llc | Direct-fed microbials and methods of their use |
US10004768B2 (en) * | 2014-09-25 | 2018-06-26 | Iryohojin Kiyokai | Treatment of atopic dermatitis and infectious dermatitis with biological spa therapy |
EA027597B1 (en) * | 2014-10-09 | 2017-08-31 | Александр Владимирович Синица | Composition with probiotic, hepatoprotective, antioxidant and immune modulating activity |
EP3294308A4 (en) | 2015-05-14 | 2019-03-06 | University of Puerto Rico | Methods for restoring microbiota of newborns |
CN105132307B (en) * | 2015-07-22 | 2017-12-12 | 江南大学 | It is a kind of applied to the composite bacillus microbial water-purifying agent of ornamental fish and its application |
DE102015010874B4 (en) * | 2015-08-25 | 2017-06-14 | Fritz Stephan Gmbh Medizintechnik | Suit for a newborn, especially a premature baby |
EP3370528B1 (en) * | 2015-10-30 | 2024-04-03 | Z Probiotics Inc. Dba Z Bioscience Inc. | Probiotic compositions and methods reducing pathogens in an environment |
WO2017117142A1 (en) | 2015-12-28 | 2017-07-06 | New York University | Device and method of restoring microbiota of newborns |
WO2017173240A1 (en) | 2016-03-31 | 2017-10-05 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
WO2017173241A1 (en) | 2016-03-31 | 2017-10-05 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
CA3019127A1 (en) * | 2016-03-31 | 2017-10-05 | Gojo Industries, Inc. | Topical composition for reducing pathogen binding |
JP2019513769A (en) * | 2016-04-19 | 2019-05-30 | ザ ユナイテッド ステイツ オブ アメリカ,アズ レプリゼンテッド バイ ザ セクレタリー,デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Use of Gram-negative species to treat atopic dermatitis |
AR108659A1 (en) * | 2016-06-03 | 2018-09-12 | Valent Biosciences Llc | NON-WATERY, NON-OILY COMPOSITIONS WITH BACILLUS AMYLOLIQUEFACIENS |
WO2018051344A1 (en) * | 2016-09-14 | 2018-03-22 | Grace Breeding Ltd. | Compositions comprising a non-pathogenic bacteria and methods for protecting plant and animal hosts from fungal, bacterial and viral diseases |
BE1024189B1 (en) * | 2016-10-28 | 2017-12-05 | Yun NV | SPRAYER WITH BACTERIAL SPECIES |
US11564879B2 (en) | 2016-11-23 | 2023-01-31 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
IT201700005552A1 (en) * | 2017-01-19 | 2018-07-19 | Copma S C A R L | EUTROFIZZANTE PRODUCT FOR COSMETIC USE |
JP6918988B2 (en) | 2017-06-06 | 2021-08-11 | サミ ラブズ リミテッド | Skin care use of extracellular metabolites derived from Bacillus coagulans |
WO2018226556A2 (en) * | 2017-06-06 | 2018-12-13 | Muhammed Majeed | Anti-aging potential of extracellular metabolite isolated from bacillus coagulans mtcc 5856 |
US11123382B2 (en) * | 2017-06-06 | 2021-09-21 | Sami Labs Limited | Hair care compositions containing extracellular metabolite preparation from Bacillus coagulans |
WO2019018944A1 (en) * | 2017-07-28 | 2019-01-31 | Davincia Inc. | Topical composition for rejuvenating and/or repairing skin, methods, uses and kits thereof |
US11633434B2 (en) | 2017-09-07 | 2023-04-25 | Technion Research & Development Foundation Limited | Topical kits and compositions and use thereof |
US20200338139A1 (en) * | 2017-12-04 | 2020-10-29 | Sami Labs Limited | Compositions for microbial anti-adhesion |
US20190169623A1 (en) | 2017-12-05 | 2019-06-06 | BioPlx, Inc. | Methods and compositions to prevent microbial infection |
US11446338B2 (en) * | 2018-05-04 | 2022-09-20 | Boris Farber | Food, cosmetic and pharmaceutical formulation with an immunomodulatory and protective anti-viral effect |
FR3085687B1 (en) * | 2018-09-07 | 2021-05-14 | Nolivade | COMPOSITION AND PRESERVATION PROCESS |
US20210378261A1 (en) * | 2018-10-02 | 2021-12-09 | Nutech Ventures | Novel gras probiotic bacterial strain to inhibit acidosis and liver abscesses in cattle |
MX2021006674A (en) * | 2018-12-05 | 2021-07-07 | Seres Therapeutics Inc | Compositions for stabilizing bacteria and uses thereof. |
CN113645959A (en) * | 2018-12-19 | 2021-11-12 | 健康牛公司 | Ready-to-use probiotic composition and uses thereof |
CN109464313A (en) * | 2019-01-22 | 2019-03-15 | 杭州百芮生物科技有限公司 | A kind of preparation method and biology cellulose diaphragm of external preparation for skin Essence |
MX2021011288A (en) * | 2019-03-19 | 2021-10-13 | Microbial Discovery Group Llc | Microbial strains for virus inhibition. |
CN113699085B (en) * | 2021-11-01 | 2022-02-08 | 渤海水产科技(滨州)有限公司 | Antagonistic bacterium ED5 and application thereof |
CN114767936B (en) * | 2022-05-10 | 2023-04-18 | 武汉理工大学 | Preparation method of composite lactobacillus casei bracket material for repairing skin injury |
CN115074286B (en) * | 2022-07-01 | 2023-06-06 | 安徽农业大学 | Bacillus pumilus for antagonizing tinea pedis pathogenic fungi and application thereof |
CN116064330A (en) * | 2023-01-10 | 2023-05-05 | 北京工商大学 | Bacillus coagulans and application thereof |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7401939A (en) * | 1974-02-13 | 1975-08-15 | Philips Nv | LOAD-CONNECTED DEVICE. |
US4062943A (en) * | 1974-11-20 | 1977-12-13 | Board Of Supervisors Louisiana State University A & M | Antibiotic produced from the microorganism (Pseudomonas lindbergii), its preparation and method of use |
US4323651A (en) * | 1974-12-04 | 1982-04-06 | R. J. Reynolds Tobacco Company | Thermostable lactase derived from bacillus |
JPS52102419A (en) * | 1976-02-23 | 1977-08-27 | Seikenkai | Lactic acid producing bacillus preparation |
US4110477A (en) | 1977-05-13 | 1978-08-29 | Kabushiki Kaisha Naruse Fermentation Laboratory | Method for producing natto containing lactic acid bacteria |
JPS55113718A (en) * | 1979-02-27 | 1980-09-02 | Yakult Honsha Co Ltd | Antitumor agent |
IE59628B1 (en) * | 1986-06-26 | 1994-03-09 | Beecham Group Plc | Treatment of fungal infections |
US5413960A (en) | 1987-05-01 | 1995-05-09 | Biogaia Ab | Antibiotic reuterin |
JPH01199575A (en) * | 1988-02-04 | 1989-08-10 | Rikagaku Kenkyusho | Novel cyclomaltodextrin-glucano transferase and production thereof |
IT1227154B (en) | 1988-08-05 | 1991-03-19 | A Tosi Farmaceutici S R L Nova | PHARMACEUTICAL COMPOSITIONS FOR GYNECOLOGICAL USE BASED ON LATTOBACILLI |
AT391323B (en) | 1989-03-10 | 1990-09-25 | Jungbunzlauer Ag | MICROORGANISM OF THE SPECIES BACILLUS COAGULANS AND A METHOD FOR THE PRODUCTION OF OPTICALLY PURE L (+) - LACTIC ACID |
US5371011A (en) * | 1989-07-10 | 1994-12-06 | Zeneca Corp. | Mold control in forage |
FR2656314B1 (en) * | 1989-12-22 | 1992-04-17 | Bp Chemicals Snc | ZIRCONIUM CATALYST SUPPORTED ON MAGNESIUM CHLORIDE, PROCESS FOR THE PREPARATION AND USE OF THE CATALYST IN OLEFIN POLYMERIZATION. |
DE4001611C1 (en) * | 1990-01-20 | 1991-02-28 | Skw Trostberg Ag, 8223 Trostberg, De | |
US5200336A (en) * | 1990-07-02 | 1993-04-06 | New England Biolabs, Inc. | Restriction endonuclease obtainable foam bacillus coagulans and a process for producing the same |
WO1992008470A1 (en) | 1990-11-14 | 1992-05-29 | Emu Products Western Australia Pty. Ltd. | Anti-inflammatory composition derived from emu oil |
IT1262927B (en) | 1992-01-14 | 1996-07-22 | Consiglio Nazionale Ricerche | EXTENDING BACTERIA AND THEIR USE AS PROBIOTICS |
FI92498C (en) * | 1992-06-10 | 1994-11-25 | Valio Meijerien | New microorganism strain, bacterial preparations containing it and their use for controlling yeast and mold |
JPH06166623A (en) * | 1992-09-25 | 1994-06-14 | Toyama Chem Co Ltd | Antimicrobial composition |
WO1994011492A1 (en) | 1992-11-12 | 1994-05-26 | Chr. Hansen's Laboratory, Inc. | Method of favorably modifying poultry intestinal microflora |
US6103246A (en) * | 1993-06-03 | 2000-08-15 | Tisdale; Carrie J. | Creams and lotions containing emu oil |
US5540920A (en) * | 1994-11-22 | 1996-07-30 | Olin Corporation | Synergistic biocide composition containing pyrithione plus an additive |
US5472713A (en) * | 1994-11-23 | 1995-12-05 | Elf Resources, Inc. | Therapeutic uses of emu oil |
SE9502588L (en) | 1995-07-13 | 1997-01-14 | Moelnlycke Ab | Inhibition of the growth of bacteria in connection with absorbent products by the addition of other bacteria |
US5698227A (en) * | 1996-07-23 | 1997-12-16 | Rivlin; Daniel | Compositions comprising lidocaine and emu oil and methods of use thereof |
ATE493139T1 (en) * | 1997-04-18 | 2011-01-15 | Ganeden Biotech Inc | SURFACE USE OF PROBIOTIC BACILLUS SPORES TO PREVENT OR CONTROL MICROBIAL INFECTIONS |
US6645506B1 (en) * | 1997-04-18 | 2003-11-11 | Ganeden Biotech, Inc. | Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil |
JP2002502430A (en) * | 1997-06-03 | 2002-01-22 | ガネデン バイオテック,インコーポレイテッド | Symbiotic lactic acid bacteria for treating bacterial infections associated with SIDS |
US7374753B1 (en) * | 1997-06-03 | 2008-05-20 | Ganeden Biotech, Inc. | Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS |
US6261577B1 (en) * | 1997-07-16 | 2001-07-17 | Symbollon Corporation | Non-staining topical iodine composition and method |
US6312703B1 (en) * | 1998-02-06 | 2001-11-06 | Lecigel, Llc | Compressed lecithin preparations |
US6811786B1 (en) * | 1999-04-01 | 2004-11-02 | Ganeden Biotech, Inc. | Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions |
CA2339643A1 (en) | 1998-08-07 | 2000-02-17 | Ganeden Biotech, Inc. | Methods for increasing the solubility of nutritional materials using probiotic lactic acid-producing bacteria |
US6461607B1 (en) * | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
CA2368509A1 (en) | 1999-04-14 | 2000-10-19 | Ganeden Biotech, Inc. | Methods for inhibiting microbial infections associated with sanitary products |
ATE270558T1 (en) * | 1999-08-26 | 2004-07-15 | Ganeden Biotech Inc | USE OF EMU OIL AS A CARRIER FOR FUNGICIDES, ANTIBACTERIAL AND ANTIVIRAL MEDICATIONS |
US6849256B1 (en) * | 1999-11-08 | 2005-02-01 | Ganeden Biotech Incorporated | Inhibition of pathogens by probiotic bacteria |
US6416772B1 (en) * | 2001-01-12 | 2002-07-09 | H. Wayne Van Engelen | Topical dermal anaesthetic |
WO2003039260A2 (en) * | 2001-11-05 | 2003-05-15 | Ganeden Biotech Inc | Probiotic compositions |
US20030143262A1 (en) * | 2001-12-13 | 2003-07-31 | Brusk Ulla Forsgren | Hygiene tissue |
US6579543B1 (en) * | 2002-02-22 | 2003-06-17 | Jackie H. McClung | Composition for topical application to skin |
-
1999
- 1999-08-26 US US09/383,975 patent/US6645506B1/en not_active Expired - Lifetime
-
2000
- 2000-07-20 US US09/620,622 patent/US6723326B1/en not_active Expired - Lifetime
- 2000-08-25 JP JP2001518064A patent/JP2003507428A/en active Pending
- 2000-08-25 DE DE60023919T patent/DE60023919T2/en not_active Expired - Lifetime
- 2000-08-25 AU AU73324/00A patent/AU783418B2/en not_active Expired
- 2000-08-25 EP EP05024273A patent/EP1632239A1/en not_active Withdrawn
- 2000-08-25 ES ES00961363T patent/ES2256036T3/en not_active Expired - Lifetime
- 2000-08-25 EP EP00961363A patent/EP1212069B1/en not_active Expired - Lifetime
- 2000-08-25 WO PCT/US2000/023300 patent/WO2001013927A2/en active IP Right Grant
- 2000-08-25 AT AT00961363T patent/ATE308988T1/en active
- 2000-08-25 CA CA2382840A patent/CA2382840C/en not_active Expired - Lifetime
-
2002
- 2002-06-28 US US10/184,665 patent/US6905692B2/en not_active Expired - Lifetime
-
2005
- 2005-06-14 US US11/152,894 patent/US7541042B2/en not_active Expired - Lifetime
-
2007
- 2007-10-12 US US11/974,427 patent/US7544363B2/en not_active Expired - Lifetime
-
2009
- 2009-06-05 US US12/479,064 patent/US7807185B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US6723326B1 (en) | 2004-04-20 |
US20090238907A1 (en) | 2009-09-24 |
JP2003507428A (en) | 2003-02-25 |
ES2256036T3 (en) | 2006-07-16 |
ATE308988T1 (en) | 2005-11-15 |
CA2382840C (en) | 2011-05-24 |
WO2001013927A3 (en) | 2001-08-30 |
US20030003107A1 (en) | 2003-01-02 |
DE60023919T2 (en) | 2006-08-10 |
CA2382840A1 (en) | 2001-03-01 |
WO2001013927A2 (en) | 2001-03-01 |
EP1212069B1 (en) | 2005-11-09 |
US7541042B2 (en) | 2009-06-02 |
US7807185B2 (en) | 2010-10-05 |
EP1632239A1 (en) | 2006-03-08 |
US6645506B1 (en) | 2003-11-11 |
AU7332400A (en) | 2001-03-19 |
AU783418B2 (en) | 2005-10-27 |
EP1212069A2 (en) | 2002-06-12 |
US20050271758A1 (en) | 2005-12-08 |
DE60023919D1 (en) | 2005-12-15 |
US7544363B2 (en) | 2009-06-09 |
US20080089963A1 (en) | 2008-04-17 |
US6905692B2 (en) | 2005-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1212069B1 (en) | Improved topical compositions containing extracellular products of probiotic bacteria and uses thereof | |
EP1212093B1 (en) | Use of emu oil as a carrier for antifungal, antibacterial and antiviral medications | |
EP0975227B1 (en) | Topical use of probiotic bacillus spores to prevent or control microbial infections | |
US7507402B1 (en) | Topical use of probiotic Bacillus spores to prevent or control microbial infections | |
AU2006201179B2 (en) | Use of Emu Oil Carrier for Antifungal, Antibacterial, and Antiviral Medications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2382840 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 73324/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000961363 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000961363 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/11-11/11, DRAWINGS, REPLACED BY NEW PAGES 1/10-10/10; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000961363 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 73324/00 Country of ref document: AU |